RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy

doi:10.21203/rs.3.rs-2200020/v5

Download PDF

Research Article

RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy

https://doi.org/10.21203/rs.3.rs-2200020/v5

This work is licensed under a CC BY 4.0 License

Version 5

posted

You are reading this latest preprint version

TDP-43 proteinopathies including frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative disorders characterized by aggregation and mislocalization of the nucleic-acid binding protein TDP-43 and subsequent neuronal dysfunction. Here, we developed endogenous models of sporadic TDP-43 proteinopathy based on the principle that disease-associated TDP-43 acetylation at lysine 145 (K145) alters TDP-43 conformation, impairs RNA-binding capacity, and induces downstream mis-regulation of target genes. Expression of acetylation-mimic TDP-43^K145Q resulted in stress-induced nuclear TDP-43 foci and loss of TDP-43 function in primary mouse and human induced pluripotent stem cell (hiPSC)-derived cortical neurons. Mice harboring the TDP-43^K145Q mutation recapitulated key hallmarks of FTLD, including progressive TDP-43 phosphorylation and insolubility, TDP-43 mis-localization, transcriptomic and splicing alterations, and cognitive dysfunction. Our study supports a model in which TDP-43 acetylation drives neuronal dysfunction and cognitive decline through aberrant splicing and transcription of critical genes that regulate synaptic plasticity and stress response signaling. The neurodegenerative cascade initiated by TDP-43 acetylation recapitulates many aspects of human FTLD and provides a new paradigm to further interrogate TDP-43 proteinopathies.

Biological sciences/Neuroscience/Diseases of the nervous system/Dementia

Biological sciences/Neuroscience/Molecular neuroscience

Biological sciences/Cell biology/Mechanisms of disease

neurodegeneration

TDP-43

proteinopathy

mouse model

TDP-43 proteinopathies are characterized by the dysfunction and aggregation of Transactivation response element DNA-binding Protein of 43 kDa (TDP-43), with ~ 95% of all amyotrophic lateral sclerosis (ALS) and ~ 50-60% of all frontotemporal lobar dementia (FTLD-TDP) cases harboring TDP-43 pathology.^1–4 There is significant neuropathologic and clinical overlap between FTLD and ALS with many individuals developing a mixed phenotype, providing strong evidence for a common FTLD/ALS spectrum of disorders.^5–9 It is also notable that TDP-43 pathology is abundant in other sporadic neurodegenerative diseases including Alzheimer disease (AD),^10,11 Limbic-Predominant Age-related TDP-43 Encephalopathy (LATE),^12,13 and Parkinson’s disease (PD).^14,15 The clinical and neuropathological overlap suggests that common pathogenic mechanisms may link TDP-43 to neurodegeneration.^16,17 However, modeling sporadic TDP-43 pathogenesis has been challenging since its expression levels are tightly regulated,^18,19 which has precluded a clear separation of TDP-43 disease-related dysfunction from general toxicity resulting from TDP-43 over- or under-expression.^20–23 Current knock-in models of TDP-43 disease-causing mutations^24–28 provide valuable insights but may be limited in their application to sporadic disease.^24–28

Under normal physiological conditions, TDP-43 resides in the nucleus to control RNA processing (RNA splicing, transport, and stability) and gene transcription.^29–31 Structurally, nuclear retention is primarily mediated by an N-terminal nuclear localization sequence (NLS) through interactions with α1/β-importins,^32,33 and association with nucleic acids is mediated by two tandem RNA recognition motifs (RRM1/RRM2),^34,35 however there is interplay between nucleic acid binding and nuclear localization.^36,37 The C-terminal glycine-rich domain (also termed the intrinsically disordered or low complexity domain) mediates protein-protein interactions^37–39 and harbors most, but not all, familial TARDBP mutations that are causative for FTLD/ALS.^40,41 In sporadic and most familial TDP-43 proteinopathies, TDP-43 undergoes nuclear depletion and concomitant nuclear or cytoplasmic accumulation and aggregation.^42–44 Both TDP-43 loss-of-function (e.g., aberrant cryptic splicing) and gain-of-function (e.g., aggregate-induced toxicity) mechanisms have been proposed as drivers of TDP-43 pathogenesis.^45–48

How TDP-43 becomes dysfunctional in sporadic disease remains unresolved, however, aberrant TDP-43 post-translational modifications (PTMs), such as phosphorylation, acetylation, and ubiquitination may play a role. PTMs modulate TDP-43’s biochemical properties leading to conformational changes, modulation of nucleic acid binding affinity, regulation of liquid-liquid phase separation (LLPS), and propensity to form insoluble TDP-43 aggregates, all of which are disease-associated phenomena.^49–51 Among the various PTMs, TDP-43 acetylation at lysine residue 145 (K145) within RRM1 has emerged as a critical regulator of both loss and gain of function toxicity.^52,53 Acetylated TDP-43 is found within TDP-43 inclusions of sporadic ALS (sALS) spinal cord motor neurons but not age-matched control tissue.⁵² Inclusions in FTLD cortex are largely composed of C-terminal fragmented TDP-43 lacking the K145 residue,^54,55 precluding an assessment of Ac-K145 in FTLD patients. However, TARDBP mutations that disrupt RNA binding, and thereby may act in a similar manner to TDP-43 acetylation, have been identified in FTLD-TDP patients (e.g. P112H and K181E),^56,57 supporting a pathogenic role for altered nucleic acid binding in disease. Mimicking TDP-43 acetylation with a lysine-to-glutamine substitution (TDP-43^K145Q) is sufficient to neutralize the positive charge, disrupt RNA binding, and induce several hallmarks of TDP-43 pathology in vitro,^52,53 supporting a model whereby TDP-43 acetylation drives both loss-of-function (e.g., RNA-binding deficiency) and gain-of-function (e.g., aggregation) toxicity.

Here, we used CRISPR/Cas9 genome editing to introduce a K145Q substitution into the endogenous mouse Tardbp gene, thereby generating acetylation-mimic TDP-43^K145Q knock-in mice, which enabled us to investigate the pathophysiological impacts of an aberrant TDP-43 PTM while leaving native upstream and downstream genomic elements intact. Using mouse cortical neurons, human hiPSC-derived cortical neurons, and aged cohorts of TDP-43^K145Q homozygous mice, we found that acetylation-mimic TDP-43^K145Q induced nuclear TDP-43 foci and cytoplasmic TDP-43 accumulation, which coincided with several disease-associated and loss-of-function measures including widespread transcriptome and splicing alterations. Finally, we observed prominent FTLD-like cognitive and behavioral deficits in acetylation-mimic TDP-43 mice that correlated with biochemical and splicing alterations in affected brain regions. Our study supports lysine acetylation of TDP-43 as a driver of dysfunction in sporadic TDP-43 proteinopathies.

Mouse neurons expressing TDP-43^K145Q undergo stress-dependent formation of nuclear TDP-43 foci and loss of TDP-43 splicing function

We originally showed that TDP-43 acetylation can promote RNA-binding deficiency, aggregation, and pathology.^52,53 We sought to expand these findings by exploring the behavior of acetylation-mimic TDP-43 variants in primary murine cortical neurons. We employed lentiviral vectors that encode either wild-type (TDP-43^wt), acetylation-deficient (TDP-43^K145R), and acetylation-mimic (TDP-43^K145Q) variants to overexpress TDP-43 species in neurons, and then examined their subcellular localization by immunofluorescence microscopy. In the absence of acute cellular stress, most neurons over-expressing TDP-43^K145Q showed distinct nuclear foci that were more prominent compared to TDP-43^wt or TDP-43^K145R constructs (Figure 1A, B). When neurons were exposed to an acute oxidative stressor (200 µM sodium arsenite), a sensitizing agent commonly used to enhance TDP-43 dysfunction,^58–61 there was a significant increase in TDP-43 foci formation with all variants (Figure 1A, C). The response in neurons expressing TDP-43^K145Q was very robust, resulting in the formation of numerous large, bright TDP-43-positive foci, as well as smaller TDP-43-positive nuclear foci. These aberrant TDP-43 structures were absent from cells expressing TDP-43^wt or acetylation-null TDP-43^K145R, indicating that acetylation-mimic TDP-43^K145Q alters TDP-43 conformation within the nucleus and sensitizes neurons to oxidative stress-induced foci formation. By coupling high content wide-field microscopy with quantitative image analysis, we observed a three-fold increase in TDP-43 foci formation in neurons expressing TDP-43^K145Q (Figure 1C).

TDP-43 overexpression can result in general toxicity and altered TDP-43 function, depending on the duration and the extent of over-expression.^20,62,63 To avoid confounding non-specific toxicity, we transitioned to a more physiologically relevant model to further elucidate the impact of RNA-binding deficient acetylation-mimic TDP-43. We employed CRISPR-Cas9 mutagenesis to introduce a single amino acid substitution at position 145 (K145Q) into the endogenous mouse Tardbp locus, thereby generating TDP-43^K145Q knock-in mice (Figure 2 - Figure supplement 1B). By targeting the native mouse gene, we avoided both TDP-43 overexpression and disruption of the Tardbp untranslated regions (UTRs).¹⁸ A TDP-43^K145Qfounder line was propagated as heterozygotes and continually re-sequenced to confirm retention and propagation of the K145Q substitution (Figure 2 - Figure supplement 1C, D). Both heterozygous and homozygous TDP-43^K145Qmice were born at normal mendelian frequencies and showed no obvious developmental defects.

We first investigated the effects of TDP-43^K145Q expression in neurons in vitro by isolating and culturing primary cortical neurons from homozygous TDP-43^K145Qmice, hereafter referred to as TDP-43^KQ/KQ mice and compared them to TDP-43^wt-derived neurons. Exposing neurons to acute oxidative stress induced more abundant TDP-43-positive nuclear foci in acetylation-mimic TDP-43^KQ/KQ neurons than in TDP-43^wt neurons (Figure 2A, B). Quantitative image analysis also revealed variable levels of nuclear clearing and cytoplasmic mislocalization of TDP-43 in TDP-43^KQ/KQneurons, however, no statistically significant differences in TDP-43 localization was found between acetylation-mimic and TDP-43^wt neurons (Figure 2A, C). Because TDP-43 foci formation is associated with loss-of-function defects,^64–66 we next investigated if TDP-43 function was impaired by evaluating endogenous targets of TDP-43 activity. We observed a trend toward increased Tardbp mRNA in TDP-43^KQ/KQ neurons at DIV 14 (Fig 2D), which was suggestive of TDP-43 loss of function and auto-regulation. We therefore investigated sortillin-1 (Sort1) mRNA splice variants, as a more sensitive endogenous indicator of loss of TDP-43-dependent splicing function. Functional nuclear TDP-43 results in the production of a mature spliced Sort1 mRNA transcript, however, in the setting of TDP-43 depletion or loss of function, TDP-43 is unable to repress the inclusion of exon 17b, generating a longer Sort1+ex17b transcript variant.^67,68 RT-qPCR analysis revealed a significant deficit in normal TDP-43 splicing function, with nearly a 10-fold increase in the ratio of Sort1+ex17b to Sort1-WT mRNA, without significant changes to total Sort1 mRNA levels in TDP-43^KQ/KQ neurons compared to controls (Fig 2E-F). Overall, these results indicate that a single endogenously expressed acetylation-mimic TDP-43^K145Q mutation can sensitize TDP-43 to conformational changes that impair its normal splicing function in mouse neurons.

Acetylation-mimic TDP-43^K145Qalters TDP-43 function in human neurons

To assess this model’s relevance to human neurons, we used CRISPR/Cas9 to generate a panel of human induced pluripotent stem cell (hiPSC) lines harboring homozygous acetylation-mimic TDP-43 (TDP-43^K145Q.12 and TDP-43^K145Q.18), acetylation-deficient TDP-43 (TDP-43^K145R.2and TDP-43^K145R.12), or unmodified TDP-43 (isogenic control, TDP-43^wt) (Figure 3 - Figure supplement 1). We confirmed appropriate editing of the TARDBP gene in each line via Sanger sequencing (Figure 3 - Figure supplement 1B), verified the pluripotency of the hiPSC clones (Figure 3 - Figure supplement 1C-E), and then differentiated each of the lines into mature cortical neurons (Figure 3 - Figure supplement 2). We then used immunofluorescent labelling and confocal microscopy to qualitatively assess the distribution and morphology of TDP-43 protein within neurons, both with and without an acute exposure to sodium arsenite. Untreated hiPSC-derived TDP-43^K145Q cortical neurons were morphologically identical to TDP-43^wt and TDP-43^K145R neurons and showed similar patterns of TDP-43 localization (Figure 3A). All hiPSC-derived lines showed a granular nuclear TDP-43 localization pattern under normal conditions, consistent with physiologic de-mixing of nuclear TDP-43.⁶⁰ Following acute oxidative stress, however, TDP-43^K145Q neurons showed apparent TDP-43 nuclear clearing and the formation of large, intensely labeled TDP-43-positive foci (Figure 3A). In comparison, cortical neurons expressing TDP-43^wt or TDP-43^K145R maintained nuclear TDP-43 and formed small stippled TDP-43 puncta. We note that TDP-43 nuclear clearing and foci formation was more robust in hiPSC-derived neurons compared to mouse neurons, suggesting human neurons may be more sensitive to TDP-43 RNA-binding deficiency. Similar to mouse neurons, hiPSC-derived TDP-43^K145R neurons were indistinguishable from TDP-43^wt neurons, supporting acetylation-induced charge neutralization as a driver of TDP-43 loss of function rather than an inherent effect of mutation at the K145 locus.

We next asked whether hiPSC-derived TDP-43^K145Q cortical neurons show more robust functional deficits compared to the mouse neuron data above. We again employed RT-qPCR to measure levels transcripts associated with TDP-43 loss of function, beginning with TARDBP as an indicator of impaired TDP-43 autoregulation. In contrast to mouse neurons, we observed an approximately 2-fold increase TARDBP mRNA in TDP-43^K145Q.12 and TDP-43^K145Q.18 neurons and a slight but significant reduction in TARDBP mRNA in TDP-43^K145R.12 neurons (Figure 3B). We then assessed TDP-43-dependent splicing activity using primers specific for human SORT1 splice variants, whose regulation by TDP-43 is conserved in mouse and humans.^67,68 The aberrant SORT1+ex17b splice variant was undetectable in TDP-43^wt neurons, but was present in 60% of TDP-43^K145Q.12 and 100% of TDP-43^K145Q.18, TDP-43^K145R.2, and TDP-43^K145R.12 neurons (Figure 3C). In samples confirmed to have detectable SORT1+ex17b transcript, levels were, on average, considerably higher levels in TDP-43^K145Q compared to TDP-43^K145R neurons. Appropriately spliced SORT1-WT and total SORT1 transcript levels were comparable across all 5 lines, with only a slight increase in total SORT1 transcript in TDP-43^K145Q.12 neurons (Figure 3D-E). We conclude that SORT1+ex17b is a low-abundance transcript that accumulates in TDP-43^K145Q neurons.

We also examined neurons for the presence of truncated STMN2 and UNC13A cryptic exon mRNA, which are implicated as ALS-FTLD biomarkers and/or risk genes.^69–72 Strikingly, truncated STMN2 mRNA was approximately 100-fold higher in both TDP-43^K145Q.12 and TDP-43^K145Q.18 neuron lines, respectively, compared to TDP-43^wt neurons, while no difference from WT was found in TDP-43^K145Rneurons. (Figure 3F). The unperturbed STMN2 splice variant (STMN2 WT) was reduced about 50% in both acetylation-mimic TDP-43^K145Q lines but unchanged in TDP-43^K145R.2 neurons (Figure 3G). We also noted a subtle increase in STMN2 WT mRNA in TDP-43^K145R neurons, suggesting the fully deacetylated state, achieved by acetylation-deficient mimics, may augment STMN2 levels. RT-qPCR analysis of cryptic exon-included UNC13A splice variant (UNC13A cryptic exon) failed to detect the abnormal splice product in TDP-43^wt and TDP-43^K145R.2 lines, with only low levels observed in some TDP-43^K145R.12 samples. In contrast, both TDP-43^K145Q lines dramatically accumulated the UNC13A cryptic exon containing mRNA (Figure 3H). The mRNA levels of the typical splice variant (UNC13A WT) were similar across all five lines (Figure 3I), indicating that the lack of detectable UNC13A cryptic exon mRNA in WT and acetylation-deficient neuron lines was not a result of reduced UNC13A expression, but rather is likely specific to a lack of cryptic splicing events. Taken together, these results demonstrate that endogenously expressed acetylation-mimic TDP-43^K145Q alters TDP-43 localization and conformation in response to stress and impairs splicing in a disease-relevant manner in human iPSC-derived neurons.

TDP-43 acetylation-mimic mice develop age-dependent cognitive and behavioral defects

To evaluate TDP-43 acetylation-mimic mice, we aged the animals and performed an extensive battery of behavioral analysis to assess cognitive and motor function, which reflect impairments that are commonly found in patients with TDP-43 proteinopathies.⁶ To be sufficiently powered to detect small differences in behavioral phenotypes, we initially focused on TDP-43^wt and homozygous TDP-43^KQ/KQ mice. Moreover, since there were no significant differences between males and females in any behavioral analyses described below, we pooled both sexes into either WT or TDP-43^KQ/KQ groups. At 12 months old, TDP-43^KQ/KQ mice showed significant reduction of body weight compared to WT littermates, and this difference was maintained until end point analysis at 18 months old (Figure 4A). Evaluation of exploratory activity and locomotion in an open field test demonstrated that TDP-43^KQ/KQ mice spend significantly more time in the center region (Figure 4B), with no differences in total distance traveled (Figure 4 - Figure supplement 3A), indicative of decreased anxiety-like behavior.^73,74 Acoustic startle testing revealed impaired prepulse inhibition (PPI) in TDP-43^KQ/KQmice at 12 months old (Figure 4 - Figure supplement 2A), indicative of deficits in sensorimotor gating, a form of inhibitory behavioral control,^75,76 which is a phenomenon that can be observed in early dementia.⁷⁷ In 18-month-old animals, evaluation of acoustic startle response and PPI was confounded by hearing impairment (Figure 4 - Figure supplement 2B), however the altered activity reflected by increased time in the center region of an open field test was maintained at this age (Figure 4B). Thus, consistent patterns of behavioral disinhibition and reduced anxiety-like behavior were apparent in TDP-43^KQ/KQ mice over time.

We next performed contextual and cue-dependent fear conditioning as an index of hippocampal and cortical function.^78–82 Context-dependent fear testing revealed reduced freezing times in TDP-43^KQ/KQ mice, with trends observed at 12 months old and significant deficits appearing at 18 months (Figure 4C). Similarly, auditory cue-dependent fear testing revealed significant impairments in associative cue learning in TDP-43^KQ/KQ mice at 12 months of age (Figure 4D), a behavior thought to be mediated by the amygdala and higher-order cortical regions important in inhibitory control.⁸³ As mentioned above, general auditory defects in both genotypes at 18 months of age confounded interpretations of any cue-dependent learning deficits at this advanced age (Figure 4D). Morris Water Maze testing was used to evaluate swimming ability and spatial learning,⁸⁴ which showed equivalent swim speeds, suggesting no motor impairments in TDP-43^KQ/KQ mice at 18 months of age (Figure 4 - Figure supplement 2D). While assessment of spatial learning showed a trend towards impaired acquisition learning (Figure 4E, F), we observed more prominent defects in reversal learning after moving the location of the platform, as determined by significant delays in escape latency. Our findings support deficits in cognitive flexibility in TDP-43^KQ/KQ mice (Figure 4G, H).⁸⁵ We also analyzed cognitive impairments in heterozygous TDP-43^wt/KQ mice, which showed a mild intermediate phenotype (Figure 4 - Figure supplement 1).

To determine any ALS-like motor phenotypes, we assessed motor function and were surprised to find no overt signs of motor impairment in TDP-43^KQ/KQ mice at 18 months of age. TDP-43^KQ/KQ mice performed similarly to WT littermates as assessed by rotarod testing (Figure 4 - Figure supplement 3C-D) and in grip strength as measured using digital force meters (Figure 4 - Figure supplement 3E). Moreover, there were no differences in swim speed or distance traveled in an open field at any age tested (Figure 4 - Figure supplement 3A, B). We note that we cannot currently exclude the possibility of more subtle motor phenotypes or the emergence of motor defects in aged mice beyond 18 months old. The preferential deficits in learning and behavioral control support an age-dependent FTLD- or dementia-like phenotype in acetylation-mimic TDP-43^KQ/KQ mice.

TDP-43^KQ/KQ mice show hallmarks of TDP-43 dysfunction in the absence of neurodegeneration

Given the preferential cognitive phenotype observed in TDP-43^KQ/KQ mice (Figure 4), we focused on the neocortex and hippocampus of aged animals. We examined neuronal density in the neocortex of 12- and 18-month-old TDP-43^wt and TDP-43^KQ/KQ mice by immunofluorescence, widefield microscopy, and quantitative image analysis of the NeuN-positive neuronal cell density and area occupied by NeuN-positive cells in the neocortex. We did not observe any evidence of neuron loss in the neocortex of TDP-43^KQ/KQ mice at 12- or 18-months of age (Figure 5A-C). Similarly, we observed no astrogliosis (GFAP intensity and area occupied by GFAP+ cells) or microgliosis (Iba1 intensity and area occupied by Iba1+ cells) in the neocortex or hippocampus (Figure 5 - Figure supplement 1).

We next evaluated TDP-43 aggregation and cytoplasmic mislocalization in 18-month-old mice, a time at which cognitive deficits were most pronounced.^17,43 We initially used confocal microscopy, and automated quantitative image analysis to assess TDP-43 morphology and localization in the neocortex and hippocampus, which did not reveal nuclear or cytoplasmic TDP-43-positive inclusions in any brain region or genotype (Figure 5D, G). In addition to searching for aggregate pathology, we also evaluated TDP-43 abundance, as measured by fluorescence intensity, in NeuN-positive neurons, as TDP-43 expression is altered in FTLD-TDP and other TDP-43 proteinopathies,^18,86–88 and visualized the single-cell resolution data using SuperPlots.⁸⁹ We observed trends toward elevated TDP-43 protein levels in the neocortex and the CA3 region of the hippocampus (Figure 5E-F, H-I) and potential subtle increases in the cytoplasmic to nuclear TDP-43 ratio within CA3 neurons (Figure 5G, J), however these effects were variable and not statistically significant. Given the technical challenge of accurate image segmentation at the subcellular level within tissue samples, we sought more sensitive methods to assess TDP-43 pathology in TDP-43^KQ/KQ mice.

We turned to an alternative biochemical approach of sequentially fractionating isolated hippocampus and neocortex tissue to generate soluble (RIPA-extracted) and insoluble (Urea-extracted) protein fractions. TDP-43^KQ/KQ mouse neocortex harbored insoluble phosphorylated TDP-43 at the disease-associated Ser409/410 locus⁹⁰ (p409/410) at 12 months of age, which was even more prominent at 18 months (Figure 6A, C), a timepoint at which TDP-43^KQ/KQmice showed behavioral and cognitive defects (Figure 4). Notably, p409/410 abundance was minimal in the hippocampus of 12-month-old TDP-43^KQ/KQmicebut increased by 18 months (Figure 6D, F), coinciding with the onset of hippocampal-mediated learning deficits (Figure 4C). Though p409/410 was elevated in TDP-43^KQ/KQmice, we were surprised to find that the total insoluble TDP-43 pool was not altered, suggesting that increased TDP-43 phosphorylation may precede overt conversion from soluble to insoluble TDP-43.

We also examined soluble TDP-43 levels, as acetylation-induced loss of function may result in autoregulatory feedback that increases the production of TDP-43.¹⁸ The soluble TDP-43 pool was significantly increased in TDP-43^KQ/KQ at 12 months in the neocortex and at 18 months in both neocortex (Figure 6A, B) and hippocampus (Figure 6D, E), an indicator of autoregulated TDP-43 protein levels. Biochemical analysis of TDP-43 solubility and phosphorylation in heterozygous TDP-43^wt/KQ animals revealed no significant differences in soluble TDP-43 or insoluble p409/410 levels compared to TDP-43^wt mice (Figure 6 - Figure supplement 1A-C, Figure 6 - Figure supplement 2A-C). To assess TDP-43 mislocalization using a biochemical approach, we performed subcellular fractionation to isolate nuclear and cytoplasmic proteins from the neocortex and hippocampus and found a striking increase in cytoplasmic TDP-43 in TDP-43^KQ/KQ mice at both 12 and 18 months of age (Figure 6G-L). Similar to the intermediate levels of cognitive decline in heterozygous TDP-43^wt/KQ mice, we observed trends toward increased cytoplasmic TDP-43 in TDP-43^wt/KQ mice, particularly at 18 months old (Figure 6 - Figure supplement 1D-I, Figure 6 - Figure supplement 2D-I).

Finally, we evaluated whether TDP-43^KQ/KQ mice show TDP-43 dysfunction in the spinal cord. Surprisingly, TDP-43^KQ/KQ mice harbored insoluble p(409/410)-TDP-43 (Figure 6 - Figure supplement 3A,C) and moderate increases in cytoplasmic TDP-43 mislocalization (Figure 6 - Figure supplement 3D-F) in the spinal cord at 18 months old, despite the lack of any overt motor deficits in TDP-43^KQ/KQ animals (Figure 4 - Figure supplement 2). We thus found that a similar biochemical signature of TDP-43 abnormalities is present in the spinal cord, yet does not correlate with motor deficits in 12- to 18-month-old mice. Our findings suggest TDP-43 phosphorylation and mislocalization occur as early events, prior to the formation of mature TDP-43 inclusion pathology and may drive the progressive FTLD-TDP-like phenotype in TDP-43^KQ/KQ mice.

Disease-linked transcriptomic and splicing defects are prevalent in acetylation-mimic TDP-43^KQ/KQ mice

TDP-43 acetylation drives RNA dissociation and loss of TDP-43 function,⁵² implying that reduced RNA-binding capacity may impact transcriptional regulation and mRNA splicing.^36,50,91 We performed total RNA sequencing to determine how mimicking TDP-43 acetylation affects RNA profiles in vivo. We examined the neocortex and hippocampus of 18-month-old TDP-43^wt or TDP-43^KQ/KQ mice, representing the regions and timepoints with the most striking biochemical and behavioral and abnormalities and identified nearly 400 differentially expressed genes (DEGs) in each brain region in TDP-43^KQ/KQ mice compared to TDP-43^wt, after correcting for underlying batch effects. As expected by acetylation-induced loss of TDP-43 function and subsequent autoregulation, the Tardbp transcript was increased (Supplementary File 1a-b). Follow-up RT-qPCR analysis confirmed a 2- to 3-fold increase in Tardbp expression in the neocortex and hippocampus (Figure 6M-N), as well as the spinal cord (Figure 7 - Figure supplement 1A), which correlated with increased TDP-43 protein levels (Figure 6B, E; Figure 6 - Figure supplement 3A-C).

We then clustered the DEGs based on their up- or down-regulation and the brain region affected (Figure 6), which revealed largely similar patterns of transcriptional alterations, with some distinct differences (Figure 7, Figure 7 - Figure supplement 2, Supplementary File 1a-b). To investigate the potential biological implications of the altered transcriptome, we performed Gene Ontology (GO) term enrichment analyses on DEGs identified in each of the six clusters (Supplementary File 1c). In both brain regions, the most highly downregulated genes were involved in developmental processes, including many related to CNS development and maintenance, such as neurogenesis (e.g., Sema5b, Rnd2, Brinp1), gliogenesis (e.g., Tlr2, Olig2, Sox10), and myelination (e.g., Nkx2-2, Nkx6-2, Sox10). Sema5b was the most dramatically reduced transcript in the hippocampus, and the third most highly reduced in the cortex, (Supplementary File 1a-b) with a two-fold reduction in expression in TDP-43^KQ/KQ mice. Downregulated genes in both the hippocampus and neocortex were also enriched for terms related to synapse homeostasis and transmembrane signaling, however the dysregulated pathways were distinct. Genes related to GABAergic synapses (e.g., Gad1, Gad2, Abat, Gnb5) were selectively downregulated in the neocortex, while trans-synaptic signaling and ion transport mechanisms (e.g., Homer3, Camk4a, Nsmf, Cnih2) were decreased in the hippocampus.

In contrast, there was significant upregulation of cellular stress response genes (Sesn1, Nrros, Plat, Klf15) and many apoptotic regulators (e.g., Trp53inp1, Pmaip1, Bcl2l1, Plekhf1) in both the hippocampus and neocortex, along with an over-representation of GO terms related to metabolism, localization, cell adhesion (Figure 7, Supplementary File 1c). Several pathways were uniquely altered including coagulation and complement cascades, which were only upregulated in the hippocampus (e.g., F3, Plat, Cd59a). Interestingly, while genes associated with trans-synaptic signaling were decreased in the hippocampus, another set of genes involved in this same pathway was upregulated in the cortex (e.g., Syt7, Synpo, Nptx1, Spg11) (Supplementary File 1c).

Given the cognitive defects in TDP-43^KQ/KQ mice, we sought to draw parallels between the TDP-43^KQ/KQ mouse and the human FTLD-TDP transcriptome. Comparison of the DEGs in TDP-43^KQ/KQ mice to the mouse orthologs of those found in FTLD-TDP frontal or temporal cortex tissue⁹² revealed marked overlap between our mouse and their human datasets (Figure 7, see “FTLD-TDP Cortex” bar), particularly in the hippocampus, as measured by statistical enrichment analyses that found over-representation of FTLD-TDP DEGs in our TDP-43^KQ/KQ dataset (Supplementary File 1d; p = 0.0003 "Hippocampus Down" vs Downregulated in FTLD-TDP frontal cortex; p = 0.0014 "Hippocampus Down" vs Downregulated in FTLD-TDP temporal cortex; p = 0.0048 "Hippocampus Up" vs Upregulated in FTLD-TDP frontal cortex). A similar alignment comparing DEGs from TDP-43^KQ/KQ mice to those following TDP-43 knockdown in mouse striatum also identified commonly altered genes, particularly in the TDP-43^KQ/KQ downregulated gene sets (Figure 7, see “TDP-43 knockdown” bar; Supplementary File 1d; p = 0.019 "Hippocampus Down" vs Downregulated in TDP-43-KD; p = 0.046 "Cortex Down + Hippocampus Down" vs Upregulated in TDP-43-KD). Taken together, we identified distinct FTLD-TDP signatures including altered synaptic gene expression and stress response signaling that reflect acetylation-induced TDP-43 dysfunction.

Alternative splicing defects, particularly impaired repression of cryptic exons, due to TDP-43 dysregulation are strongly implicated in FTLD and ALS pathogenesis.^{71,72,93–96} In line with our findings above that TDP-43^KQ/KQ mouse primary cortical neurons in vitro show splicing deficits (Figure 2E-F), we identified widespread splicing alterations in vivo. Analysis of TDP-43^KQ/KQ neocortex identified 289 differentially spliced genes (DSGs), with 81.7% of loci containing at least one cryptic splice junction, and 29.8% containing two cryptic splice junctions (Supplementary File 1e). In the hippocampus, we found 126 DSGs, 77.0% of which contain a cryptic splice junction and 41.3% that are formed by two cryptic splice sites (Supplementary File 1f). The alternative splicing events were relatively consistent between brain regions, as over 70% of the DSGs identified in the hippocampus were also present in the cortex. Among the most significant DSGs identified were known TDP-43 splicing targets (e.g., Kcnip2, Pdp1, Poldipp3, Ppfibp1, Dnajc5. Tmem2, Sort1),^24,94,97 transcripts associated with particular neurodegenerative diseases (e.g., Mapt, Atxn1, Lrrk2),^98–104 and also many robustly altered transcripts that are poorly characterized but linked to neurodegeneration (e.g., Nrxn3, Nos1, Arfgef2, Arhgap10, Lrp8, Smarca4, Rims2). Of all identified DSGs, the most substantially altered transcript was Sort1, encoding the Sortilin-1 (Sort1) protein. We noticed that exclusion of a Sort1 3’ exon was reduced by 55.9% in TDP-43^KQ/KQ cortex and by 57.0% in the hippocampus (Figure 8A), such that the aberrantly spliced Sort1 transcript was the predominant variant detected, comprising nearly 80% of all Sort1 transcripts, aligning with our findings from TDP-43^KQ/KQ primary mouse cortical neurons.

SORT1, the human homolog of mouse Sort1, is a highly expressed neurotrophic factor receptor that binds progranulin (PGRN) and regulates endosomal/lysosomal function through a pathway that is genetically linked to FTLD-TDP.^105–109 Because TDP-43 depletion results in SORT1 exon 17b inclusion, this leads to the production of a soluble and putatively toxic SORT1 variant that is increased in FTLD-TDP patients.^67,68,97 To confirm that the altered 3’ splicing in our sequencing data was indeed Sort1 exon 17b inclusion, we performed qPCR using primers specific for the mouse Sort1+ex17b transcript or the appropriately spliced variant (Sort1-WT), and a primer pair that recognizes all Sort1 variants (Sort1 total) on tissues isolated from TDP-43^KQ/KQ or WT mice.⁶⁷ We found the ratio of aberrant Sort1-ex17b to appropriately spliced Sort1-WT was increased approximately 10-fold in the neocortex (Figure 8B) and hippocampus (Fig 8C) of TDP-43^KQ/KQ mice at both 12- and 18-months of age, which corroborates our RNA sequencing analysis showing that the exon-included Sort1+ex17b variant predominates in these tissues. The total level of Sort1 transcript in vivo varied with age, with slightly increased levels at 12 months and reduced levels at 18 months of age, suggestive of a negative feedback mechanism regulating Sort1 expression. Spinal cord tissue revealed similar levels of abnormal Sort1 splicing in TDP-43^KQ/KQ animals at 12- and 18-months of age, however total Sort1 mRNA expression did not significantly change with age (Figure 7 - Figure supplement 1B-C).

To determine whether the Sort1+ex17b transcript in TDP-43^KQ/KQ mice leads to the generation of a distinct Sort1 protein product, we immunoblotted hippocampus and cortex homogenates and identified a higher molecular weight Sort1 variant in TDP-43^KQ/KQ compared to WT mice (Figure 8D, E), consistent with Sort1 exon 17b inclusion. The abnormal Sort1 protein showed decreased steady-state stability in TDP-43^KQ/KQ mice, as suggested by reduced protein levels in acetylation-mimic animals, compared to controls (Figure 8F, G). These data are strongly suggestive of failure to repress exon inclusion in TDP-43^KQ/KQ mice, leading to an altered Sort1-progranulin axis and supporting an aberrant splicing profile that resembles alterations seen in human FTLD-TDP.

Here, we developed novel neuronal and mouse models of RNA binding-deficient acetylation-mimic TDP-43 (TDP-43^K145Q). Using a combination of molecular, cellular, and transcriptomic readouts combined with in vivo behavioral assays, we provide evidence that aberrant TDP-43^K145Q recapitulates key hallmarks of TDP-43 proteinopathies, including altered TDP-43 solubility and localization, impaired autoregulation, and abnormal splicing function. Taken together, our findings suggest that TDP-43 acetylation-induced dysfunction likely contributes to disease progression.

Our prior mass spectrometry analysis originally identified acetylated lysines K145 and K192,⁵² though a more recent study identified residues K84 (within the NLS) and K136 (within RRM1) as additional lysine residues of interest.⁶⁴ Any normal physiological or cellular role for TDP-43 acetylation remains unclear. However, given its impact on RNA binding, one can imagine TDP-43 acetylation may fine-tune TDP-43’s normal nuclear and cytoplasmic functions, but becomes corrupted due to aging and/or stress exposure.¹¹⁰ It is likely that acetylation within the RRMs generally impairs TDP-43 RNA-binding function, as multiple studies have shown that acetylation mimic TDP-43^K136Q or TDP-43^K145Q variants phenocopy one another, with both showing nuclear foci formation and reduced affinity for target RNAs. Therefore, deficiency in RNA binding may explain why acetylation, or acetylation-mimic mutations within RRM1, alter TDP-43 dynamics and lead to pathology. Indeed, RNA-binding deficient TDP-43, including RRM mutations or deletions, showed increased TDP-43 phase separation, aggregation, nuclear egress, and neurotoxicity.^34,64,66,111 Conversely, enhancing RNA binding was suggested to mitigate these phenotypes,^65,112,113 in part due to TDP-43 retention within the nucleus.³⁶ Thus, impaired RNA binding achieved by excessive lysine acetylation, or other RRM modifications, likely promotes TDP-43 pathogenesis in the form of mislocalization, aggregation, RNA dysregulation, and impaired autoregulation, as we observe with the TDP-43^K145Qmodels described in this study.

Primary TDP-43^KQ/KQ knock-in mouse and human iPSC-derived cortical neurons formed nuclear TDP-43+ foci that were exacerbated by acute oxidative stress. The acetylation-induced loss of RNA binding likely destabilized TDP-43 thus creating a more aggregate-prone conformation that can be further modulated by stressors (e.g, sodium arsenite) and likely other factors. Based on our original description of these TDP-43 foci, and several recent studies of acetyl-mimic TDP-43 variants,^64,66,114 the nuclear TDP-43+ foci observed in our neuronal models likely represent a spectrum of phase-separated structures, including anisosomes,⁶⁶ and more immobile gel-like or solid aggregates. Future studies are needed to determine the molecular composition of these TDP-43+ foci, which could lead to a better understanding of their biogenesis, progression, and perhaps their dissolution. For example, it is conceivable that re-establishing TDP-43/RNA interactions could alleviate TDP-43 foci formation, suppress aggregation, and provide potential therapeutic avenues to consider.¹¹⁵

Homozygous TDP-43^KQ/KQ knock-in mice showed impaired cognitive function, as well as behavioral disinhibition in the absence of overt motor deficits up to 18-months of age, supporting a FTLD-like phenotype in this model. The progressive behavioral defects and parallel increases in insoluble phosphorylated TDP-43 in the neocortex and hippocampus are also consistent with age as a driver of the FTLD-TDP phenotype. Even heterozygous TDP-43^wt/KQ mice showed intermediate levels of both cognitive impairment and biochemical perturbations when compared to wild-type and homozygous littermates, suggesting a dose-dependent effect of TDP-43 acetylation. We were surprised to find no overt motor deficits at 18-months-old despite the presence of mislocalized and phosphorylated TDP-43 in the spinal cord of TDP-43^KQ/KQ mice. We speculate this could be due to any of the following non-mutually exclusive possibilities. 1) The levels of insoluble phosphorylated TDP-43 in the spinal cord have not crossed a critical threshold required for functional decline. 2) There is a time-dependent delay in the accumulation of TDP-43 and the onset of motor symptoms that could emerge beyond 18 months, which will require additional studies in aged cohorts of mice. 3) Spinal motor neurons in mice may possess some intrinsic resilience that suppresses functional decline. 4) It is possible that TDP-43^KQ/KQ mice do indeed show subtle motor deficits that could be detected by more sensitive measures, such as electromyography-based techniques,^116,117 for which future studies are warranted. 5) Finally, it remains plausible that phosphorylated TDP-43 is not inherently toxic or associated with functional decline in the spinal cord or other tissues.^118,119

TDP-43^KQ/KQ mice show striking similarities to other TDP-43 depletion models. For example, the RNA profiles in TDP-43^KQ/KQ brain, particularly the hippocampus, were similar to a mouse model of striatal TDP-43 knock down (Figure 7), including upregulation of immune response genes (Serpine1, Serping1) and altered splicing of TDP-43 targets (Kcnip2, Sort1, Dnajc5, Pdp1, Poldip3).⁹⁷ Similar splicing deficits were found in conditional CAMKIIa-driven Tardbp knockout mice, accompanied by an FTLD-like phenotype with disinhibitory behavior and spatial learning deficits resembling those seen in TDP-43^KQ/KQ mice.^120,121 Hippocampal knockdown of TDP-43 in adult mice impaired learning and memory, likely due to synaptic loss.¹²² This aligns with our finding of cognitive decline without overt cortical neuron loss or neurodegeneration. We suspect that TDP-43 loss of function causes synaptic dysfunction that may eventually lead to neurodegeneration beyond 18 months. In contrast to the lethality associated with complete TDP-43 depletion²³, the K145Q substitution creates a powerful yet viable partial loss of function model, which lacks developmental defects and ALS-like motor phenotypes. In addition, transcript profiles in TDP-43^KQ/KQ mice do not entirely align with striatal TDP-43 knockdown.⁹⁷ This is likely in part because the K145Q mutation retains some level of RNA binding capacity, leaving some TDP-43-dependent processes unperturbed. Acetylated TDP-43 could also lead to gain-of-function toxicity due to altered RNA binding patterns and conformational instability, leading to nuclear export, enhanced phosphorylation and aggregation, and a dysregulated transcriptome, as we observe in TDP-43^KQ/KQ mice. Both loss and gain of function effects have been proposed for familial disease-causing TARDBP mutations,^45,46,94,123 and TDP-43 acetylation may act in a similar manner.

RNA sequencing revealed profound transcriptomic alterations within aged TDP-43^KQ/KQ mouse brains. Many up- and down-regulated transcripts identified in acetylation-mimic mice were also differentially expressed in FTLD-TDP human tissue (Figure 7), particularly genes associated with cellular stress response, synaptic regulation, apoptotic signaling, and cellular adhesion.^92,124 Disease-related alternative splicing events were also common in TDP-43^KQ/KQ neurons and mouse brain. For example, the altered splicing of Sort1 and subsequent generation of Sort1+ex17b observed in TDP-43 acetylation-mimic mice (Figure 8) are also observed in FTLD-TDP brain.^67,106 Moreover, SORT1 facilitates the endocytosis and lysosomal degradation of PGRN,^106,108 a protein whose deficiency is causative of 10-30% familial FTLD cases.^125–127 In humans, SORT1+ex17b contains an additional proteolytic site, resulting in the production of a soluble toxic variant that impairs the function of SORT1, prevents binding to PGRN and impacts neuronal survival.^67,105 A recent study showed that TDP-43 depletion increased SORT1+ex17b, impaired brain derived neurotrophic factor (BDNF) signaling, and reduced synaptic plasticity in mice.⁶⁸ Importantly, hiPSC-derived cortical neurons expressing acetylation-mimic TDP-43^K145Q showed impaired splicing of putative FTLD-ALS spectrum disease biomarkers UNC13A and STMN2.^69–72 We speculate that acetylated TDP-43 alters SORT1/PGRN signaling, as well as other pathways critical to neurotransmission, contributing to the synaptic dysregulation that is so evident in our transcriptome data. Future mechanistic studies are aimed at interrogating SORT1-PGRN, UNC13A, and STMN2-related signaling pathways in TDP-43^KQ/KQ mice and hiPSC-derived neurons.

Other aberrantly spliced transcripts in TDP-43^KQ/KQ mice provide additional insight into pathogenic mechanisms. The synaptic regulators Arfgef2¹²⁸ and Arhgap10^129,130 were among the most affected transcripts. Concurrently, Sema5b which regulates synaptic connections and axon guidance,^131–134 was strongly downregulated in TDP-43^KQ/KQ hippocampus and cortex, as were other genes involved in synapse homeostasis and signaling. Furthermore, splicing of LRP8 (low-density lipoprotein receptor-related protein 8) was significantly altered in TDP-43^KQ/KQ mice, and abnormalities in LRP8 can cause learning and memory defects, likely by disrupting Reelin-mediated synaptic plasticity and long-term potentiation (LTP).^135–138 Similarly, Nos1, encoding the neuronal nitric oxide synthase (nNOS) protein that regulates LTP and synaptic plasticity via the production of nitric oxide,^139,140 showed aberrant splicing patterns in TDP-43^KQ/KQmice. Importantly, all of these synaptic regulators (Nos1, Lrp8, Argef2, Sema5b) and other significantly altered splice variants (e.g., Adipor2, Mapk14, Smarca4, Sort1, Mapt) have been linked to AD and other neurodegenerative diseases.^{99,138,140–148} Our transcriptome data strongly suggests that splicing and transcriptional abnormalities due to TDP-43 acetylation impacts synaptic plasticity, neurotransmission, and neuronal survival pathways in the TDP-43^KQ/KQ model, which overlaps with abnormalities found in human FTLD-TDP patients. We suspect that this prominent RNA signature may underlie the cognitive decline in TDP-43^KQ/KQ neocortex and hippocampus.

Given the correlation between TDP-43 acetylation and FTLD-TDP presented in this study, it is perhaps surprising that acetylated TDP-43 (detected with an acetylation-specific ac-K145 antibody) is found within ALS spinal cord inclusions but has not yet been detected in FTLD-TDP cortex.⁵² However, TDP-43 pathology in FTLD-TDP cases is dominated by the presence of C-terminal fragments lacking RRM1 thereby precluding detection of the acetylated K145 site.^54,149 It remains possible that TDP-43 acetylation still occurs in FTLD-TDP at one or more additional lysine residues, and thus future mass spectrometry studies will be needed to determine whether a TDP-43 acetylation profile occurs earlier in the progression of FTLD-TDP.

In conclusion, disrupting RNA-binding with an acetylation mimic TDP-43^K145Qmutation results in an age-dependent, dementia-like phenotype characterized by many signatures of FTLD, including progressive cognitive deficits, TDP-43 mislocalization and phosphorylation, impaired autoregulation, and prominent RNA dysregulation. Interrogation of the affected genes linked TDP-43 acetylation to many known FTLD-associated pathways, including STMN2, SORT1, and stress response signaling, while also pinpointing new putative factors as mediators of disease pathogenesis. By developing new human and mouse models of TDP-43 acetylation, we expand our understanding of sporadic TDP-43 proteinopathies and provide valuable approaches to identify and test new avenues for therapeutics that target pathogenic mechanisms underlying TDP-43 proteinopathy.

Animal Husbandry

Mice were housed in ventilated microbarrier cages on racks providing HEPA filtered air supply to each cage. Animals were kept on a 12hr light-dark cycle with access to food and water ad libitum. All animal husbandry, experiments, and procedures were performed in strict compliance with animal protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the University of North Carolina at Chapel Hill (Protocol #21.257).

Primary neuron cultures

Murine primary cortical neurons were performed using wild-type C57Bl/6 mice (Charles River) or TDP-43^wt/KQ breeding pairs. Timed pregnant females at embryonic day 15-16 were lethally anesthetized with isoflurane. The abdominal cavity was opened, and the uterus incised to remove the placentas and embryonic sacs, which were washed briefly in ice-cold 70% ethanol and then placed in cold HEPES-buffered Bank’s balanced salt solution (HBSS). The embryos were transferred into a 10cm dish containing cold HBSS, the embryos removed from the amniotic sac, and the brains were extracted from the cranium. For TDP-43^wt/KQ dissections, process was paused for approximately 2 hours to permit genotyping of the fetuses, during which the brains were stored at 4° C protected from light in a Hibernate-E (BrainBits NC9063748) solution supplemented with B27 (Gibco 17504044) and GlutaMAX (ThermoFisher 35050061). After genotyping, if applicable, the cerebral cortices from each brain were isolated under a stereomicroscope, pooled by genotype, minced with forceps, and digested for 30min at 37°C in a filter-sterilized HBSS solution containing 20U/mL papain (Worthington Biochemical LS003126), 1mM EDTA, 0.2mg/mL L-cysteine, and 5U/mL DNAse (Promega M6101). The enzyme solution was removed, and the digested tissue was washed twice with sterile HBSS. Warm plating media [BrainPhys media (Stemcell 05790), 5% fetal bovine serum, 1x penicillin/streptomycin (Gibco 15140122), 1x B27, 1x GlutaMAX] containing 5U/mL DNAse, was added and the tissue was dissociated mechanically using a P1000 pipette. The resulting cell suspension was spun down for 5min at 1.5rcf to pellet the cells, resuspended in plating media, and filtered through a 40 mm cell strainer. Cells were counted using a hemocytometer and plated onto poly-D-lysine (PDL)-coated 12-well tissue culture plates (Corning 356470) at 300K cells/well (for RNA extraction) or 96-well glass bottom black wall plates (Cellvis P96-1.5H-N) at 30K/well (for immunofluorescence and microscopy). 16-24hours after plating, all plating media was removed and replaced with neuronal cell media (BrainPhys, 1x GlutaMAX, 1x B27, 1x penicillin/streptomycin). Cultures were incubated at 37°C, 5% CO₂and 95% humidity with half-media exchanges every 3 days for the duration of all experiments.

Lentivirus preparation and neuron transduction

Lentiviral vectors were constructed in-house using the pUltra vector as a backbone for cloning via restriction enzyme digestion followed by ligation. The pUltra construct was acquired from Addgene (gift from Malcolm Moore; Addgene plasmid # 24129 ; http://n2t.net/addgene:24129 ; RRID:Addgene_24129)¹⁵⁰. To generate TDP-43 constructs, TDP-43 variant gene fragments were PCR amplified using TDP-43 F’ and R’ primers (Supplementary File 3) and a pcDNA5/TO- myc-TDP-43^wt, -myc-TDP-43^K145Q,or -myc-TDP-43^K145Rplasmid⁵² as the template. The pUltra construct was digested with AgeI and BamHI, and then incubated with the appropriate TDP-43 PCR product in the presence of T4 DNA ligase and T4 Polynucleotide Kinase for 1 hour at room temperature. The resulting ligation product was transformed into NEB stable competent cells using standard protocols.

Lentiviral production was performed by co-transfecting (CalPhos™ Mammalian Transfection Kit, TakaRa 631312) 37.5 μg lenti-plasmid with 25 μg psPAX2, 12.5 μg VSVG, and 6.25 μg REV for each 15 cm dish of lenti-X 293T cells (Takara 632180) and 3 dishes of cells were used for each lentiviral production. 3 days after transfection, culture media were collected and centrifuged at 2000g for 10 min. Lentiviral particles were purified using a double-sucrose gradient method. Briefly, the supernatants were loaded onto a 70%-60%-30%-20% sucrose gradient and centrifuged at 70,000g for 2 hr at 17°C (Beckman Optima LE-80K Ultracentrifuge, SW 32 Ti Swinging-Bucket Rotor). The 30%-60% fraction containing the viral particles was retrieved, resuspended in PBS, filtered with a 0. 45μm filter flask before loaded onto a 20% sucrose cushion, and centrifuged a second time at 70,000g for 2 hr at 17°C. The supernatants were carefully discarded, and the viral particles present in the pellet were resuspended in PBS, aliquoted and stored at -80°C.

Lentivirus aliquots were evaluated for neuronal transduction ability prior to each experiment and diluted to approximately equal concentrations of effective virus. Lentiviral transductions were performed on DIV10 for a DIV14 harvest or DIV24 for a DIV28 harvest. In brief, lentiviruses were diluted to a 2x concentration in neuronal media, and then added to plates via half-media exchange. 24 hours after viral transduction, all virus-containing media was removed and replaced with 50% fresh neuronal media and 50% conditioned media from plates containing WT non-transduced neurons. Neurons were then cultured to DIV14 or DIV28 as the experiment required.

hiPSC-derived cortical neurons

iPSC maintenance: The HPC26 iPSCs were maintained on Matrigel-coated dishes (Corning 354480) in StemFlex Medium (Thermo FisherScientific A3349401) and passaged every 3-4 days with 0.5 mM EDTA dissociation solution as previously described¹⁵¹.
CRISPR/Cas9 genome editing: We used a control wildtype HPC26 cell line¹⁵¹ to generate two separate point mutations in the TARDBP gene that encodes the TDP-43 protein. Both mutations created single amino acid substitutions to change lysine 145 to glycine or arginine (K145Q and K145R). Benchling was used to design two guide RNAs and the corresponding single-stranded DNA donor oligos. The guide RNAs were purchased from Synthego, and the donor oligos from IDT. Genome editing was performed as described in Battaglia et. al¹⁵². Briefly, 3x10⁵ iPSCs were electroporated on the Neon electroporation system (Thermo Fisher Scientific) with recombinant protein complexes made of Cas9 v2 protein (Thermo Fisher Scientific A36498), 900 ng sgRNA-TARDBP and 2700 ng of single-stranded donor oligonucleotide-K145Q or donor oligonucleotide-K145R (Supplementary File 3). Seventy-two hours after electroporation, cells were plated for single cell screening on a 96-well plate format using the limited dilution method. After two weeks, single cells were expanded, genome DNA collected and the exon 4 of TARDBP amplified using the specific primers Ex4Fr and Ex4Rv (Supplementary File 3). Screening for single or double allele gene edits was perform by Sanger sequencing (Figure 3 - Figure supplement 1a-c).
Characterization of edited iPSC clones: Stemness edited iPSCs was assessed by immunofluorescent staining of the pluripotency factors OCT4, SOX2, SSEA4 and Tra-1-60 using specific antibodies (Supplementary File 4) as described¹⁵¹ (Figure 3 - Figure supplement 1d-e). To confirmed stemness and differentiation capabilities of the edited iPSCs we used the Taqman hPSC Scorecard (ThermoFisher A15871) as described in Battaglia et al¹⁵². Briefly, iPSCs were differentiated into all three germ layers using STEMdiff Trilineage Differentiation Kit (StemCell Technologies), a mono- layer based protocol to directly differentiate hES cells in parallel into the three germ layers. Non-differentiated and differentiated cells were lysed and total RNA purified using the RNeasy kit (QIAGEN 74004). RNA reversed transcription was performed with the high-capacity cDNA Reverse Transcription kit (ThermoFisher 4368813) following the Taqman Scorecard’s manufacture guidelines. qRT-PCR was carried out using the QuantStudio 7 Flex Real-Time PCR system. The TaqMan PCR assay combines DNA methylation mapping, gene expression profiling, and transcript counting of lineage marker genes¹⁵³.
iPSC-derived cortical neurons: We adapted, modified and standardized a protocol to generate mature cortical neurons from iPSCs using a dual SMAD inhibition protocol^154,155. First, undifferentiated iPSCs were collected with Accutase, counted and 3x10⁵cells cultured in StemScale PSC medium (A4965001) supplemented with 10 µM Y27632 (PeproTech 1293823) and cultured in suspension on an orbital shaker at 37 C and 5% CO₂. After 48 hours, cells were dissociated with Accutase and 3x10⁵cells differentiated into NPCs as neutrosphere in StemScale PSC medium supplemented with 10 µM Y27632 (PeproTech 1293823) and 1.5 µM CHIR99021 (PeproTech 2520691),10 µM SB431542 (PeproTech 3014193) and 50 nM LDN-193189 (Sigma SML0755). CHIR99021 was removed after 24 hours and cells were cultured for 10 days with daily medium changes and neurospheres dissociated at 1:3 ratio twice a week. Then NPCs were expanded for 7 days in the presence of 20 ng/ml FGF (Peprotech 100-18B) in Neuronal Expansion Medium [1:1 Advanced DMEM/F12 (12634028) and Neural Induction Supplement (A1647801)]. NPCs were plated for maturation on PDL/Laminin coated plates or coverslips in cortical neuron maturation medium [1:1 Advanced DMEM/F12 and Neurobasal; 1X GlutaMAX, 100mM B-mercaptoethanol, 1x B27, 0.5x N2, 1x NEAA and 2.5 mg/ml insulin (Sigma-Aldrich I9278)] supplemented with 10 ng/ml BDNF, 10 ng/ml GDNF, and 10 uM DAPT. Seventy-two hours after plating, cells were treated with 1 µg/ml Mitomycin C for (Sigma M5353) for 1 hour. Cellular identity was assessed specific markers of neuronal progenitor (PAX6, SOX2, and SOX1), and mature neurons (MAP2, TUJ1, CTIP2 and SATB2) (Figure 3 - Figure supplement 2) (Supplementary File 4). All reagents were purchased from ThermoFisher unless otherwise noted.

Primary mouse neuron and hiPSC-derived cortical neuron arsenite treatments and immunocytochemistry

On DIV14 (mouse primary neurons) or mature hiPSC-derived cortical neurons (~DIV50), neurons were treated for 2 hours with 200µM sodium arsenite (NaAsO₂) or vehicle (molecular biology grade water). Following treatment, neurons were fixed with 4% paraformaldehyde (PFA) in 1x phosphate buffered saline (PBS) and washed with 1xPBS. Neurons were permeabilized with 0.3% Triton X-100 in 1xPBS for 15min at RT, blocked in an 8% normal goat serum (NGS) 0.2% Triton X-100 in 1xPBS solution for 1-2 hours at RT, and incubated with primary antibodies (Supplementary File 4) diluted in 4% NGS, 0.2% Triton X-100, 1xPBS solution overnight at 4°C. The next day, the neurons were washed with 1xPBS, followed by application of fluorescent secondary antibodies (Supplementary File 4) diluted in 4% NGS, 0.2% Triton X-100, 1xPBS solution for 2 hours at RT, covered. Cells were washed four times with 1xPBS, with the third wash containing 1µg/mL 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI). 96-well plates were preserved in an 85% glycerol in 1xPBS solution containing 0.4% sodium azide for microbial prevention. Coverslips were mounted onto pre-cleaned glass slides using ProLong^TM Diamond Antifade Mountant (Invitrogen P36961).

Cultured neuron fluorescence microscopy and image analysis

Mouse primary cortical neurons in 96-well plates were visualized via automated fluorescence microscopy using EVOS M7000 Imaging System (ThermoFisher AMF7000) equipped with Olympus 20x/0.75 NA UPlanSApo and Olympus 40x/0.95 NA UPlanSApo objectives, and the following filter cubes: DAPI (357/44 nm Excitation; 447/60 nm Emission), GFP (482/25 nm Excitation; 524/24 nm Emission), Texas Red (585/29 nm Excitation; 628/32 nm Emission), and Cy5.5 (655/40 nm Excitation; 794/160 nm Emission). Images were acquired in an automated fashion, using DAPI fluorescence as the autofocus substrate, taking 16-32 images per well of 2-3 wells per experimental condition. Automated quantitative image analysis was performed using CellProfiler 4.0^156,157 to measure TDP-43 fluorescence intensity within neuronal compartments and to count TDP-43-positive foci within neurons. To identify neurons and subcellular compartments, DAPI was used to delineate nuclei and NeuN was used to label neuronal soma. hiPSC-derived cortical neurons were imaged on a Leica SP8X Falcon confocal microscope equipped with a 63x/1.40 NA Plan Apochromatic (oil) objective and hybrid GaAsP detectors, Leica Application Suite X Life Sciences software (Leica, Wetzlar, Germany).

Mouse model generation and genotyping

CRISPR/Cas9 Reagents

Cas9 guide RNAs targeting the mouse Tardbp K145 codon were identified using Benchling software (Benchling, San Francisco, CA, USA). Three guide RNAs were selected for activity testing. Guide RNAs were cloned into a T7 promoter vector followed by in vitro transcription and spin column purification (RNeasy, Qiagen). Guide RNAs were tested for cleavage activity by in vitro cleavage assay. Each guide RNA was incubated with Cas9 protein (UNC Protein Expression and Purification Core Facility) and PCR-amplified guide RNA target site. The products were run on an agarose gel for analysis of target site cleavage. Based on this assay, the guide RNA selected for genome editing in embryos was Tardbp-g79T (Supplementary File 3). The donor oligonucleotide for insertion of the K145Q and silent genotyping mutations was Tardbp-K145Q-T (Supplementary File 3). Two silent mutations were induced to create a unique HinfI restriction enzyme digestion site and permit genotyping by PCR and gel electrophoresis.

C57BL/6J zygotes were microinjected with microinjection buffer (5 mM Tris-HCl pH 7.5, 0.1 mM EDTA) containing 1) 20 ng/ul Cas9 mRNA, 10 ng/ul g79T guide RNA and 50 ng/ul donor oligonucleotide (founder #9) or 2) 20 ng/ul Cas9 mRNA, 400 nM Cas9 protein, 10 ng/ul g79T guide RNA and 50 ng/ul donor oligonucleotide (founders #23, 26, 39, 44, 53). Injected embryos were implanted in recipient pseudopregnant females and resulting pups were screened by PCR and sequencing for the presence of the desired mutant allele. Founder lines were propagated as heterozygotes and regularly sequenced to confirm retention of the K145Q and silent mutations.

We assessed the likelihood of off-target mutations using prediction algorithms to ensure low likelihood of off-target effects. The Benchling MIT off-target score for Tardbp-g79T is 72¹⁵⁸, and the CRISPOR-generated MIT off-target score is 86. CRISPOR also gave a Cutting frequency determination score of 86^159–161. Moreover, all of the predicted exonic off-target sites from CRISPOR have 4 mismatches, making them unlikely to be mutated. Sequencing of the founder lines and their progeny did not detect any insertions or deletions within a 550bp region surrounding the Tardbp locus.

TDP-43^K145Q mouse line genotyping

Each mouse was genotyped prior to any experimental use. DNA was extracted from ear punch or toe clip tissue using the HotSHOT method¹⁶². PCR amplification of the modified Tardbp locus was performed with ApexRed master mix (Genesee Scientific 42-138B) and TDPKQ F’ and TDPKQ R’ primers (Supplementary File 3) using the following cycling parameters: 95°C denaturation for 3min; 15 cycles of 95°C for 30sec, 72°C for 30sec then -1°C per cycle, 72°C 60sec; 25 cycles of 95°C for 30sec, 58°C for 30sec, 72°C for 60sec; 72°C extension for 5min. The PCR product was then incubated with HinfI enzyme (New England Biosystems R0155S) in CutSmart buffer (New England Biosystems B7204) for 1hr at 37°C. Digested PCR products were separated on a 2% agarose Tris-acetate-EDTA gel containing SybrSafe stain (Invitrogen S33102) and visualized on an ImageQuant LAS4000 machine.

Mouse Behavior

All testing was performed by experimenters blinded to mouse genotype.

Open field. Exploratory activity in a novel environment was assessed by a one-hour trial in an open field chamber (41 cm x 41 cm x 30 cm) crossed by a grid of photobeams (VersaMax system, AccuScan Instruments). Counts were taken of the number of photobeams broken during the trial in five-minute intervals, with separate measures for locomotor activity (total distance traveled) and vertical rearing movements. Time spent in the center region was used as an index of anxiety-like behavior.

Conditioned fear. Mice were evaluated for conditioned fear using the Near-Infrared image tracking system (MED Associates, Burlington, VT). The procedure had the following phases: training on Day 1, a test for context-dependent learning on Day 2, and a test for cue-dependent learning on Day 3.
Training. On Day 1, mice were placed in the test chambers, contained in sound-attenuating boxes. The mice were allowed to explore the novel chambers for 2 minutes before presentation of a 30-sec tone (80 dB), which co-terminated with a 2-sec scrambled foot shock (0.4 mA). Mice received 2 additional shock-tone pairings, with 80 sec between each pairing, and were removed from the test chambers 80 sec following the third shock.
Context- and cue- dependent learning. On Day 2, mice were placed back into the original conditioning chambers for a test of contextual learning. Levels of freezing (immobility) were determined across a 5-min session. On Day 3, mice were evaluated for associative learning to the auditory cue in another 5-min session. The conditioning chambers were modified using a Plexiglas insert to change the wall and floor surface, and a novel odor (dilute vanilla flavoring) was added to the sound-attenuating box. Mice were placed in the modified chamber and allowed to explore. After 2 min, the acoustic stimulus (an 80 dB tone) was presented for a 3-min period. Levels of freezing before and during the stimulus were obtained by the image tracking system.

Grip strength. Grip strength was evaluated using precision force gauges. Measures were based on paw grasp of a metal grid by a mouse gently pulled by the tail. Digital force meters (Chatillon DFIS-10; Largo, FL) were mounted on an acrylic platform (San Diego Instruments), with two different grids: a left-hand grid for the front paws, and a right-hand grid for all-four paws. Each grid connected to a force transducer, which provided measures of peak force (newtons). Each mouse was given 3 trials, with at least one minute between each trial. Each trial had 2 components: front-paw measures from the left-hand grid, immediately followed by all-four-paw measures from the right-hand grid.

Rotarod. Subjects were tested for motor coordination and motor learning on an accelerating rotarod (Ugo Basile, Stoelting Co., Wood Dale, IL). For the first test, mice were given three trials, with 45 seconds between each trial. Two additional trials were given 48 hours later. Rpm (revolutions per minute) was set at an initial value of 3, with a progressive increase to a maximum of 30 rpm. across five minutes (the maximum trial length). Measures were taken for latency to fall from the top of the rotating barrel.

Morris water maze. The water maze was used to assess spatial and reversal learning, swimming ability, and vision. The water maze consisted of a large circular pool (diameter = 122 cm) partially filled with water (45 cm deep, 24-26o C), located in a room with numerous visual cues. The procedure involved three separate phases: a visible platform test, acquisition in the hidden platform task, and a test for reversal learning (an index of cognitive flexibility).

Visible platform test. Each mouse was given 4 trials per day, across 2 days, to swim to an escape platform cued by a patterned cylinder extending above the surface of the water. For each trial, the mouse was placed in the pool at 1 of 4 possible locations (randomly ordered), and then given 60 sec to find the visible platform. If the mouse found the platform, the trial ended, and the animal was allowed to remain 10 sec on the platform before the next trial began. If the platform was not found, the mouse was placed on the platform for 10 sec, and then given the next trial. Measures were taken of latency to find the platform and swimming speed via an automated tracking system (Noldus Ethovision).

Acquisition and reversal learning in a hidden platform task. Following the visible platform task, mice were tested for their ability to find a submerged, hidden escape platform (diameter = 12 cm). Each mouse was given 4 trials per day, with 1 min per trial, to swim to the hidden platform. The criterion for learning was an average group latency of 15 sec or less to locate the platform. Mice were tested until the group reached criterion, with a maximum of 9 days of testing. When the group reached criterion (on day 5 in the present study), mice were given a 1-min probe trial in the pool with the platform removed. Selective quadrant search was evaluated by measuring the number of crosses over the location where the platform (the target) had been placed during training, versus the corresponding area in the opposite quadrant. Following the acquisition phase, mice were tested for reversal learning, using the same procedure as described above. In this phase, the hidden platform was re-located to the opposite quadrant in the pool. As before, measures were taken of latency to find the platform. On day 5 of testing, the platform was removed from the pool, and the group was given a probe trial to evaluate reversal learning.

Acoustic startle test. This procedure was used to assess auditory function, reactivity to environmental stimuli, and sensorimotor gating. The test was based on the reflexive whole-body flinch, or startle response, that follows exposure to a sudden noise. Measures were taken of startle magnitude and prepulse inhibition, which occurs when a weak prestimulus leads to a reduced startle in response to a subsequent louder noise.

Mice were placed into individual small Plexiglas cylinders within larger, sound-attenuating chambers. Each cylinder was seated upon a piezoelectric transducer, which allowed vibrations to be quantified and displayed on a computer (San Diego Instruments SR-Lab system). The chambers included a ceiling light, fan, and a loudspeaker for the acoustic stimuli. Background sound levels (70 dB) and calibration of the acoustic stimuli were confirmed with a digital sound level meter (San Diego Instruments). Each session began with a 5-min habituation period, followed by 42 trials of 7 different types: no-stimulus (NoS) trials, trials with the acoustic startle stimulus (AS; 40 msec, 120 dB) alone, and trials in which a prepulse stimulus (20 msec; either 74, 78, 82, 86, or 90 dB) occurred 100 msec before the onset of the startle stimulus. Measures were taken of the startle amplitude for each trial across a 65-msec sampling window, and an overall analysis was performed for each subject's data for levels of prepulse inhibition at each prepulse sound level (calculated as 100 - [(response amplitude for prepulse stimulus and startle stimulus together / response amplitude for startle stimulus alone) x 100].

Tissue harvest and preparation

At each end point, mice were anesthetized deeply with isoflurane and euthanized via rapid decapitation. The hippocampus and neocortex were dissected out of the brain on a cold surface using clean surgical tools, placed into cryo-safe nuclease-free microcentrifuge tubes, flash frozen in liquid nitrogen (LN2), and stored at –80C until processing. Frozen tissue was then pulverized in LN2-cooled stainless steel Cryo-Cups using cold stainless-steel pestles and transferred into cold nuclease-free microcentrifuge tubes and immediately stored at –80C until use.

Solubility fractionation, nucleo-cytoplasmic fractionation, and immunoblotting

All steps of protein fractionation were performed on ice unless otherwise indicated. For solubility fractionation, pulverized tissue was suspended in 5µL/mg of ice-cold 1xRIPA buffer (50mM Tris pH 8.0, 150mM NaCl, 1%NP-40, 5mM EDTA, 0.5% sodium deoxycholate, 0.1%SDS) containing a mix of protease, phosphatase, and deacetylase inhibitors [1µg/mL Peptstatin A (Sigma P4265), 1µg/mL Leupeptin (Sigma L2023), 1µg/mL N_α-Tosyl-L-lysine chloromethyl ketone hydrochloride (TPCK) (Sigma T7254), 1µg/mL Trypsin inhibitor (Sigma T9003), 1µg/mL N-p-Tosyl-L-phenylalanine chloromethyl ketone (TLCK) (Sigma T4376), 0.67µg/mL trichostatin A, 10mM nicotidamide, 1mM phenyline thanosulfyl fluoride, 1mM phenylmethylsulfonyl fluoride]. The solution was homogenized by sonication and centrifuged at 4°C for 45min at 18000xrcf. The supernatant was removed and saved as the RIPA-soluble (“soluble”) protein fraction. The pellet was resuspended in RIPA buffer with inhibitor mixture, sonicated, and centrifuged as described above, and the supernatant discarded. The resulting pellet of RIPA-insoluble material was resuspended in approximately 1µL/µg of Urea buffer (7M urea, 2M Thiourea, 4%CHAPS, 30mM Tris, pH 8.5) with the inhibitor mixture (as above), sonicated to homogenize, and centrifuged at room temperature (RT) for 45min at 21000xrcf. The resulting supernatant of RIPA-insoluble, urea-soluble protein fraction was saved as the “insoluble” protein fraction.

Nuclear and cytoplasmic soluble proteins were isolated using the Thermofisher NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific 78835) per the manufacturer’s instructions, with the addition of the protease, phosphatase, and deacetylase inhibitors (as above) to each buffer.

All soluble protein fractions were analyzed by BCA assay (Thermo Scientific 23225) to determine protein concentration. Equal quantities of protein per sample were run onto 4-20% Tris-Glycine SDS-PAGE gels (Biorad 5671095) under reducing conditions and then transferred onto nitrocellulose membranes. Total transferred protein (TTP) was assessed using PonceauS (Research Products International Corp P56200) protein stain on nitrocellulose membranes per manufacturer’s instructions. Membranes were washed three times in TBST, once in TBS, and blocked in 2% nonfat milk in 1xTBS for 1-2 hours at RT. Membranes were incubated with primary antibodies (Supplementary File 4) diluted in 2% milk overnight at 4°C. The primary antibody solution was removed and membranes washed three times in TBST, once in TBS, and incubated with cross adsorbed HRP-conjugated goat secondary antibodies (Supplementary File 4) diluted in 2% milk at 1:10000 or 1:2000 for soluble or insoluble protein immunoblots, respectively, for 1-2 hours at RT. Blots were then visualized by chemiluminescent imaging using an ImageQuant LAS4000 machine. Densitometry analysis to quantify western blot images was performed in LI-COR Image Studio Lite (Lincoln, NE, USA).

Mouse brain RNA isolation, RNA sequencing, and data analysis

Mouse brain tissue was isolated, flash frozen, and pulverized as described above. Approximately 20mg of pulverized brain tissue per sample was used to isolate RNA. 1mL of TRIzol (Invitrogen 15596018) was added to each nuclease-free eppendorf tube containing pulverized tissue, and tissues were lysed via trituration with a P1000 pipette tip, followed by trituration with a 21G and then a 25G needle on a 1mL syringe. Samples were centrifuged at 4°C for 5min at 10,000rcf to remove tissue debris. The supernatant was removed and added to a new tube containing 200uL of chloroform, which were mixed by inversion and cooled on ice for 5min. Samples were centrifuged at 4°C for 15min at 10,000rcf, and the upper aqueous phase containing RNA was transferred into a new tube, followed by the addition of 100uL of isopropanol to precipitate RNA and overnight incubation at -20°C. The next day, samples were centrifuged at top speed (18,000rcf) for 20min at 4°C to pellet the RNA. The pellets were washed twice with 1mL of ice-cold 70% molecular biology grade ethanol and then air dried for 15min at RT. The RNA pellets were resuspended in 20uL of nuclease-free water. On-column DNAse digestion and RNA clean-up was then performed using the Qiagen RNeasy mini kit (Qiagen, Inc. 74106) per manufacturer’s instructions, followed by elution in nuclease-free water.

RNA concentration was assessed using Qubit® RNA BR Assay Kit (Q10210) and a Qubit® 3.0 Fluorometer. RNA integrity was assessed using an Agilent 4150 TapeStation system and associated RNA screen tape reagents (Agilent 5067-5576). Only samples with an estimated RNA integrity number (RIN) ≥7.0 were sent to the New York Genome Center (NYGC) for bulk total RNA sequencing. Upon receipt at NYGC, RNA samples were re-evaluated for quantification and integrity, using Ribogreen and Fragment Analyzer 5300, respectively. Total RNA libraries were prepped using Kapa Total library prep with Ribo-Erase, in accordance with manufacturer recommendations. Briefly, 500ng of total RNA was used for ribosomal depletion and fragmentation of total RNA. Depleted RNA underwent first and second strand cDNA synthesis. cDNA was then adenylated, ligated to Illumina sequencing adapters, and amplified by PCR (using 9 cycles). The cDNA libraries were quantified using Fragment Analyzer 5300 (Advanced Analytical) kit FA-NGS-HS (Agilent DNF-474-1000) and Spectramax M2 (Molecular Devices) kit Picogreen (Life Technologies P7589). Libraries were sequenced on an Illumina NovaSeq sequencer, using paired end sequencing (2 x 100 bp cycles) to a depth of >75M read pairs per sample.

Raw reads were then trimmed and filtered of adapter sequencing using cutadapt¹⁶³ and filtered such that at least 90% of bases had a quality score of at least 20. Reads were then aligned to the reference mouse genome (mm10, RefSeq gene annotations) using STAR v2.5.2b¹⁶⁴, and transcript abundance was estimated using salmon¹⁶⁵. Differential expression between TDP43-KQ and TDP43-WT cortex and hippocampus was then detected using DESeq2 v1.34.0¹⁶⁶ in R v4.1.0¹⁶⁷, using a design that corrects for both mouse sex and litter effects. These batch effects were also removed from the VST-normalized expression values using limma¹⁶⁸. The correlation between Log2 fold change values between differentially expressed genes in the cortex and hippocampus was determined and Pearson correlation coefficient and two-sided p-value were computed by ggpubr stat_cor^169,170, and the smoothed linear model was fit using geom_smooth with method="lm".

Differentially expressed genes (padj < 0.05) were then separated into 6 groups based on their intersections between the two brain regions using UpSetR v1.4.0¹⁷¹ and plotted with ComplexUpset¹⁷². Normalized expression values were then centered around the mean of TDP43-WT for each respective brain region and plotted with ComplexHeatmap¹⁷³. Gene Ontology enrichments were then assessed using gprofiler2 v0.2.1^174,175 and summarized using simplifyEnrichment v1.7.2¹⁷⁶. Previously published differentially expressed genes from Hasan et al⁹² and Polymenidou et al⁹⁷ were retrieved from the respective publications; significant over-enrichments as well as human gene symbol mappings to mouse orthologs were performed using gprofiler2 (g:Orth). Differential splicing analyses were performed on splice junctions extracted from genome-aligned BAM files using regtools and LeafCutter¹⁷⁷, where tests compared TDP43-KQ to TDP43-WT correcting for sex for each brain region. Results were then summarized and visualized using LeafViz¹⁷⁸.

Quantitative RT-PCR

RNA was isolated from mouse brain tissue as described above. For RT-PCR experiments involving mouse primary cortical neurons or human iPSC-derived cortical neurons, cells were washed with 1xPBS, harvested from the culture dish, and RNA was extracted using the Qiagen RNeasy mini kit (Qiagen, Inc. 74106) with on-column DNAse digestion per manufacturer’s instructions. RNA concentration was determined using a NanoDrop 2.0 spectrophotometer, 250ng-1µg of RNA was used to generate cDNA using Applied Biosystems High-capacity RNA-to-cDNA kit (#4387406) per manufacturer’s instructions. cDNA was generated from 250-500ng of RNA using Applied Biosystems High-capacity RNA-to-cDNA kit (#4387406) per manufacturer’s instructions. Quantitative PCR was performed on a QuantStudio 6 Real Time PCR system (with Thermo Fisher Design & Analysis Software version 2.6.0) using PowerUp SYBR Green master mix (Applied Biosystems A25776). The PCR phase consisted of 40 cycles of 15s at 95°C and 1min at 60°C. Forward and reverse primer sequences for Tardbp, Sort1-WT, Sort1-total, Sort1-ex17b, TARDBP, SORT1-WT, SORT1-ex17b, SORT1-total, UNC13A, UNC13A cryptic exon, STMN2, truncated STMN2 and the reference genes β-Actin, Pgk1, and RPLP0 are listed in Supplementary File 3. Relative quantification of transcripts was performed using the Pflaff method¹⁷⁹ with both β-Actin and Pgk1 as reference genes for mouse tissue and mouse primary neurons, and RPLP0 used as the reference gene for hiPSC-derived neurons. Primers generated for this paper were designed using PrimerBank¹⁸⁰ and synthesized by Integrated DNA Technologies (IDT).

Tissue Collection, Staining, and Immunofluorescence

Mice were transcardially perfused with 1xPBS followed by 4% PFA, and brains were removed and post-fixed for 24 hours in 4% PFA. Brains were cryoprotected in 15% sucrose in 1xPBS for 24hrs followed then 30% sucrose in 1xPBS for 48hrs, and then embedded in Fisher Tissue-Plus OCT compound (4585). Forebrain (~Bregma +1.78 mm), midbrain (~Bregma +0.50 mm), and hippocampal (~Bregma -1.94 mm) 10 mm cryosections were collected onto Superfrost Plus charged slides using a Leica CM1950 cryostat.
Luxol Fast Blue and Cresyl Violet staining. Slides were acclimated to room temperature and rinsed in distilled water. They were then incubated in 70% ethanol for ~60 hours followed by 95% ethanol for 30 minutes. Tissues were stained with 0.1% Luxol Fast Blue Solution overnight at 60°C, rinsed in distilled water, and differentiated as needed by 0.05% Lithium Carbonate followed by 70% ethanol. They were then counterstained with 0.1% Cresyl Echt Violet, rinsed in distilled water, and differentiated again by 95% ethanol. Finally, slides were dehydrated in 100% ethanol, cleared in Xylene, and coverslipped with DPX mountant (Millipore-Sigma 44581).
Immunofluorescence. Slides were acclimated to room temperature and rinsed in distilled water. Heat-induced epitope retrieval was performed at 120°C using pH 6.0 buffer (Epredia, TA-135-HBL). The tissues were then blocked in 10% normal goat serum for 1 hour. Primary antibodies were applied overnight at 4°C: Mouse Anti-NeuN (clone A60) conjugated to Alexa Fluor 555 (Millipore, MAB377A5), and Rabbit Anti-TDP-43 (Cell Signaling, 89789) or Rabbit anti-Iba1 (Wako, 019-19741) and mouse anti-GFAP conjugated to Alexa Fluor 488 (Cell Signaling, 3655) (Supplementary File 4). After rinsing, secondary antibodies were applied for 2 hours at room temperature: Alexa Fluor 488 Goat Anti-Rabbit IgG (Invitrogen, A32731) or Alexa Fluor 680 Goat anti-Rabbit IgG (Invitrogen 32734). All antibodies were diluted using Da Vinci Green Diluent (Biocare Medical, PD900L). Finally, slides were coverslipped using Fluorogel II with DAPI (Electron Microscopy Sciences, 17985-50).

Tissue microscopy and Image Analysis

Brain sections stained with Cresyl Violet (CV) and brain sections labelled with Iba1 and GFAP anatibodies were imaged on a Nikon Eclipse Ti2 widefield microscope equipped with a Nikon DS-Fi3 CMOS color camera (for CV imaging) and a pco.edge 4.2Q High QE sCMOS camera (PCO, Kelheim, Germany) using a 20x/0.5 NA Plan Fluor objective and NIS-Elements software (Nikon, Minato City, Tokyo, Japan). Immunofluorescently labeled brain sections were imaged on a Leica SP8X Falcon confocal microscope equipped with hybrid GaAsP detectors using a 40x/1.30 NA Plan Apochromatic (oil) objective and Leica Application Suite X Life Sciences software (Leica, Wetzlar, Germany). Cell counting (density of CV-positive and NeuN-positive cells), as well as TDP-43 fluorescence intensity, TDP-43 localization measurements, GFAP fluorescence intensity and area, and Iba1 fluorescence intensity and area were performed using CellProfiler^156,157. Prior to quantifying TDP-43 immunofluorescence intensity and prior to confocal image segmentation, immunofluorescent images were denoised using NIS-Elements Batch Denoise.ai under default conditions. Prior to quantifying Iba1 and GFAP fluorescence characteristics, images of the necortex and hippocampus were cropped to exclude fluorescent signal from the corpus callosum. Within CellProfiler, the Cellpose 2.0 plugin^181,182 was used to perform neuron identification and the subcellular segmentation of nucleus and cytoplasm within neurons. DAPI fluorescence was used to identify nuclei, and NeuN immunoreactivity was used to identify neuronal nuclei and the surrounding soma. Images were pseudocolored and formatted for publication using Fiji ImageJ¹⁸³.

Statistical Analysis

Statistical analysis of RNA sequencing data was performed as described above. For data shown in figures 1B-C, 2B-C, 4B-C, 4E-F, and 4H-I, we used Linear Mixed Effects (LME) Models with random intercept to allow for an animal or a well specific effect. Restricted Maximum likelihood (REML) approach was used for parameter estimation. For Fig 1B-C and 2B-C, wells were used as a “by-subject” random effect. For Fig 4B-C, animals were used as a “by-subject” random effect. For 4E-F and 4H-I, animal ID and image ID were included as nested random effects. Either genotype or treatment group were included as fixed effects in each LME model. Results are presented as fixed effect estimates, standard errors and 95% confidence intervals (CI) (See Supplementary File 2). All statistical analyses were performed in R version 4.2.1 (R Core Team, 2022). Complete case analysis was considered, with P < .05 determining statistical significance. All other data was analyzed in GraphPad Prism Version 9.4.1 for Windows, GraphPad Software, San Diego, California USA, www.graphpad.com. For data sets with n>10, outliers were identified and removed (if any) using the ROUT method¹⁸⁴ at Q=1%. Details regarding the statistical test performed, sample sizes, and what the data points and error bars represent can be found in the appropriate figure legends. All statistical tests were two-sided. Statistical significance was determined as p<0.05. Supplementary statistical information about data presented in main and supplemental figures can be found in the figure’s accompanying source data files.

DATA AVAILABILITY

The TDP-43^K145Q mouse line is now available at the Mutant Mouse Resource and Research Center (MMRRC) at University of North Carolina at Chapel Hill, an NIH-funded strain repository, with the following identifiers (RRID:MMRRC_068119-UNC). Raw and processed RNA-seq data have been deposited to the Gene Expression Omnibus (GEO) under accession GSE216294. All data generated in this work are included in the manuscript and the supporting files. Any plasmids or lentiviruses generated in this study are available upon request.

ACKNOWLEDGEMENTS

We would like to thank Dale Cowley and the UNC Animal Models Core Facility for their creation of the TDP-43^K145Q mouse line and the initial sequencing. We also thank Natallia Riddick and the UNC Mouse Breeding and Colony Management Core for their assistance in animal husbandry and breeding. Confocal and Nikon Ti2 widefield microscopy was performed at the UNC Neuroscience Microscopy Core (RRID:SCR_019060), supported, in part, by funding from the NIH-NINDS Neuroscience Center Support Grant P30 NS045892 and the NIH-NICHD Intellectual and Developmental Disabilities Research Center Support Grant P50 HD103573, and core director Michele Itano assisted in image analysis protocol design. We are grateful for the UNC Histology Research Core for their assistance in tissue processing and staining. RNA sequencing was performed by the New York Genome Center. The research reported in this publication was supported by the National Institute on Aging (grant F30AG072786), the National Institute on Neurologic Disorders and Stroke (grants R01NS105981, P30NS045892, F31NS122242), the National Institute of General Medical Sciences (grants 1T32GM133364-01A1, 5T32GM008719-19), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grants U54HD079124; P50HD103573), and the National Center for Advancing Translational Sciences (grant UM1TR004406) of the National Institutes of Health. We also received support from the Department of Defense (grant AL180038) and the Muscular Dystrophy Association (grant MDA573414 and NINDS (P30NS045892).

CONFLICT OF INTEREST

The authors have no conflicts of interest to be disclosed.

1. Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006).

2. Neumann, M., Kwong, L. K., Sampathu, D. M., Trojanowski, J. Q. & Lee, V. M.-Y. TDP-43 Proteinopathy in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis: Protein Misfolding Diseases Without Amyloidosis. Arch. Neurol. 64, 1388–1394 (2007).

3. Cairns, N. J. et al. TDP-43 in Familial and Sporadic Frontotemporal Lobar Degeneration with Ubiquitin Inclusions. Am. J. Pathol. 171, 227–240 (2007).

4. Hogan, D. B. et al. The Prevalence and Incidence of Frontotemporal Dementia: a Systematic Review. Can. J. Neurol. Sci. 43, S96–S109 (2016).

5. Burrell, J. R. et al. The frontotemporal dementia-motor neuron disease continuum. The Lancet 388, 919–931 (2016).

6. Geser, F., Lee, V. M.-Y. & Trojanowski, J. Q. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: A spectrum of TDP-43 proteinopathies. Neuropathol. Off. J. Jpn. Soc. Neuropathol. 30, 103–112 (2010).

7. Burrell, J. R., Kiernan, M. C., Vucic, S. & Hodges, J. R. Motor Neuron dysfunction in frontotemporal dementia. Brain 134, 2582–2594 (2011).

8. Giordana, M. T. et al. Dementia and cognitive impairment in amyotrophic lateral sclerosis: A review. Neurol. Sci. 32, 9–16 (2011).

9. Geser, F. et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch. Neurol. 66, 180–189 (2009).

10. Meneses, A. et al. TDP-43 Pathology in Alzheimer’s Disease. Mol. Neurodegener. 16, 84 (2021).

11. Tomé, S. O. et al. Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: relationship with clinical phenotypes. Acta Neuropathol. Commun. 8, 61 (2020).

12. Besser, L. M., Teylan, M. A. & Nelson, P. T. Limbic Predominant Age-Related TDP-43 Encephalopathy (LATE): Clinical and Neuropathological Associations. J. Neuropathol. Exp. Neurol. 79, 305–313 (2020).

13. Nelson, P. T. et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142, 1503–1527 (2019).

14. Poulopoulos, M., Levy, O. & Alcalay, R. The Neuropathology of Genetic Parkinson’s Disease. Mov. Disord. 27, 831–842 (2012).

15. Nakashima-Yasuda, H. et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. (Berl.) 114, 221–229 (2007).

16. Gao, J., Wang, L., Huntley, M. L., Perry, G. & Wang, X. Pathomechanisms of TDP-43 in neurodegeneration. J. Neurochem. 146, 7–20 (2018).

17. Boer, E. M. J. de et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry 92, 86–95 (2021).

18. Budini, M. & Buratti, E. TDP-43 Autoregulation: Implications for Disease. J. Mol. Neurosci. 45, 473 (2011).

19. Ayala, Y. M. et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 30, 277–288 (2011).

20. Xu, Y.-F. et al. Wild-Type Human TDP-43 Expression Causes TDP-43 Phosphorylation, Mitochondrial Aggregation, Motor Deficits, and Early Mortality in Transgenic Mice. J. Neurosci. 30, 10851–10859 (2010).

21. Igaz, L. M. et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Invest. 121, 726–738 (2011).

22. Yang, C. et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. 111, E1121–E1129 (2014).

23. Kraemer, B. C. et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. (Berl.) 119, 409–419 (2010).

24. Fratta, P. et al. Mice with endogenous TDP‐43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 37, (2018).

25. White, M. A. et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat. Neurosci. 21, 552 (2018).

26. Huang, S.-L. et al. A robust TDP-43 knock-in mouse model of ALS. Acta Neuropathol. Commun. 8, 3 (2020).

27. Stribl, C. et al. Mitochondrial Dysfunction and Decrease in Body Weight of a Transgenic Knock-in Mouse Model for TDP-43 *. J. Biol. Chem. 289, 10769–10784 (2014).

28. Ebstein, S. Y., Yagudayeva, I. & Shneider, N. A. Mutant TDP-43 Causes Early-Stage Dose-Dependent Motor Neuron Degeneration in a TARDBP Knockin Mouse Model of ALS. Cell Rep. 26, 364-373.e4 (2019).

29. Buratti, E. & Baralle, F. E. The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol. 7, 420–429 (2010).

30. Tollervey, J. R. et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 2011 144 14, 452–458 (2011).

31. Cohen, T. J., Lee, V. M. Y. & Trojanowski, J. Q. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol. Med. 17, 659–667 (2011).

32. Doll, S. G. et al. Recognition of the TDP-43 nuclear localization signal by importin α1/β. Cell Rep. 39, 111007 (2022).

33. Pinarbasi, E. S. et al. Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci. Rep. 8, 7083 (2018).

34. Kuo, P.-H., Chiang, C.-H., Wang, Y.-T., Doudeva, L. G. & Yuan, H. S. The crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition for UG- and TG-rich nucleic acids. Nucleic Acids Res. 42, 4712–4722 (2014).

35. Lukavsky, P. J. et al. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat. Struct. Mol. Biol. 20, 1443–1449 (2013).

36. Duan, L. et al. Nuclear RNA binding regulates TDP-43 nuclear localization and passive nuclear export. Cell Rep. 40, 111106 (2022).

37. Ayala, Y. M. et al. Structural determinants of the cellular localization and shuttling of TDP-43. J. Cell Sci. 121, 3778–3785 (2008).

38. Buratti, E. & Baralle, F. E. TDP-43: gumming up neurons through protein–protein and protein–RNA interactions. Trends Biochem. Sci. 37, 237–247 (2012).

39. Budini, M. et al. Cellular Model of TAR DNA-binding Protein 43 (TDP-43) Aggregation Based on Its C-terminal Gln/Asn-rich Region. J. Biol. Chem. 287, 7512–7525 (2012).

40. Pesiridis, G. S., Lee, V. M.-Y. & Trojanowski, J. Q. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum. Mol. Genet. 18, R156-162 (2009).

41. Sreedharan, J. et al. TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis. Science 319, 1668–72 (2008).

42. Kawakami, I., Arai, T. & Hasegawa, M. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol. (Berl.) 138, 751–770 (2019).

43. Neumann, M. Molecular Neuropathology of TDP-43 Proteinopathies. Int. J. Mol. Sci. 10, 232–246 (2009).

44. Mackenzie, I. R. A. & Neumann, M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J. Neurochem. 138, 54–70 (2016).

45. Cascella, R. et al. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies. J. Biol. Chem. 291, 19437–19448 (2016).

46. Diaper, D. Loss and gain of Drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. Hum Mol Genet 22, 1539–1557 (2013).

47. Lee, E. B., Lee, V. M.-Y. & Trojanowski, J. Q. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 13, 38–50 (2011).

48. Vanden Broeck, L., Callaerts, P. & Dermaut, B. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis? Trends Mol. Med. 20, 66–71 (2014).

49. François-Moutal, L. et al. Structural Insights Into TDP-43 and Effects of Post-translational Modifications. Front. Mol. Neurosci. 12, 301 (2019).

50. Sternburg, E. L., Gruijs da Silva, L. A. & Dormann, D. Post-translational modifications on RNA-binding proteins: accelerators, brakes, or passengers in neurodegeneration? Trends Biochem. Sci. 47, 6–22 (2022).

51. Buratti, E. TDP-43 post-translational modifications in health and disease. Expert Opin. Ther. Targets 22, 279–293 (2018).

52. Cohen, T. J. et al. An acetylation switch controls TDP-43 function and aggregation propensity. Nat. Commun. 6, (2015).

53. Wang, P., Wander, C. M., Yuan, C. X., Bereman, M. S. & Cohen, T. J. Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program. Nat. Commun. 8, 1–15 (2017).

54. Igaz, L. M. et al. Enrichment of C-Terminal Fragments in TAR DNA-Binding Protein-43 Cytoplasmic Inclusions in Brain but not in Spinal Cord of Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Am. J. Pathol. 173, 182–194 (2008).

55. Chhangani, D., Martín-Peña, A. & Rincon-Limas, D. E. Molecular, functional, and pathological aspects of TDP-43 fragmentation. iScience 24, 102459 (2021).

56. Agrawal, S., Jain, M., Yang, W. & Yuan, H. S. Frontotemporal dementia‐linked P112H mutation of TDP‐43 induces protein structural change and impairs its RNA binding function. Protein Sci. Publ. Protein Soc. 30, 350–365 (2021).

57. Chen, H.-J. et al. RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy. Brain 142, 3753–3770 (2019).

58. Dewey, C. M. et al. TDP-43 Is Directed to Stress Granules by Sorbitol, a Novel Physiological Osmotic and Oxidative Stressor. Mol. Cell. Biol. 31, 1098–1108 (2011).

59. Colombrita, C. et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J. Neurochem. 111, 1051–1061 (2009).

60. Gasset-Rosa, F. et al. Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. Neuron 102, 339-357.e7 (2019).

61. Cohen, T. J., Hwang, A. W., Unger, T., Trojanowski, J. Q. & Lee, V. M. Y. Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. EMBO J. 31, 1241–1252 (2012).

62. Ash, P. E. A. et al. Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum. Mol. Genet. 19, 3206–3218 (2010).

63. Yang, C. et al. Low-level overexpression of wild type TDP-43 causes late-onset, progressive neurodegeneration and paralysis in mice. PLOS ONE 17, e0255710 (2022).

64. Garcia Morato, J. et al. Sirtuin-1 sensitive lysine-136 acetylation drives phase separation and pathological aggregation of TDP-43. Nat. Commun. 13, 1223 (2022).

65. Mann, J. R. & Donnelly, C. J. RNA modulates physiological and neuropathological protein phase transitions. Neuron 109, 2663–2681 (2021).

66. Yu, H. et al. HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science 371, eabb4309 (2021).

67. Prudencio, M. Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor. Proc Natl Acad Sci USA 109, 21510–21515 (2012).

68. Tann, J. Y., Wong, L.-W., Sajikumar, S. & Ibáñez, C. F. Abnormal TDP-43 function impairs activity-dependent BDNF secretion, synaptic plasticity, and cognitive behavior through altered Sortilin splicing. EMBO J. 38, e100989 (2019).

69. Brown, A.-L. et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603, 131–137 (2022).

70. Prudencio, M. et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J. Clin. Invest. 130, 6080–6092 (2020).

71. Melamed, Z. et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 22, 180–190 (2019).

72. Ma, X. R. et al. TDP-43 represses cryptic exon inclusion in the FTD–ALS gene UNC13A. Nature 603, 124–130 (2022).

73. Carola, V., D’Olimpio, F., Brunamonti, E., Mangia, F. & Renzi, P. Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behaviour in inbred mice. Behav. Brain Res. 134, 49–57 (2002).

74. Seibenhener, M. L. & Wooten, M. C. Use of the Open Field Maze to Measure Locomotor and Anxiety-like Behavior in Mice. J. Vis. Exp. JoVE 52434 (2015) doi:10.3791/52434.

75. Gómez-Nieto, R., Hormigo, S. & López, D. E. Prepulse Inhibition of the Auditory Startle Reflex Assessment as a Hallmark of Brainstem Sensorimotor Gating Mechanisms. Brain Sci. 10, 639 (2020).

76. Mena, A. et al. Reduced Prepulse Inhibition as a Biomarker of Schizophrenia. Front. Behav. Neurosci. 10, (2016).

77. Ueki, A., Goto, K., Sato, N., Iso, H. & Morita, Y. Prepulse inhibition of acoustic startle response in mild cognitive impairment and mild dementia of Alzheimer type. Psychiatry Clin. Neurosci. 60, 55–62 (2006).

78. Chen, C., Kim, J. J., Thompson, R. F. & Tonegawa, S. Hippocampal lesions impair contextual fear conditioning in two strains of mice. Behav. Neurosci. 110, 1177–1180 (1996).

79. Curzon, P., Rustay, N. R. & Browman, K. E. Cued and Contextual Fear Conditioning for Rodents. in Methods of Behavior Analysis in Neuroscience (ed. Buccafusco, J. J.) (CRC Press/Taylor & Francis, 2009).

80. Phillips, R. G. & LeDoux, J. E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav. Neurosci. 106, 274–285 (1992).

81. Kim, J. J. & Jung, M. W. Neural circuits and mechanisms involved in Pavlovian fear conditioning: A critical review. Neurosci. Biobehav. Rev. 30, 188–202 (2006).

82. Marschner, A., Kalisch, R., Vervliet, B., Vansteenwegen, D. & Büchel, C. Dissociable Roles for the Hippocampus and the Amygdala in Human Cued versus Context Fear Conditioning. J. Neurosci. 28, 9030–9036 (2008).

83. Sierra-Mercado, D., Padilla-Coreano, N. & Quirk, G. J. Dissociable Roles of Prelimbic and Infralimbic Cortices, Ventral Hippocampus, and Basolateral Amygdala in the Expression and Extinction of Conditioned Fear. Neuropsychopharmacology 36, 529–538 (2011).

84. Vorhees, C. V. & Williams, M. T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 1, 848–858 (2006).

85. Nicholls, R. E. et al. Transgenic mice lacking NMDAR-dependent LTD exhibit deficits in behavioral flexibility. Neuron 58, 104–117 (2008).

86. Mishra, M. et al. Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol. (Berl.) 114, 81–94 (2007).

87. Gitcho, M. A. et al. TARDBP 3’-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol. (Berl.) 118, 633–645 (2009).

88. Chen-Plotkin, A. S. et al. Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Hum. Mol. Genet. 17, 1349–1362 (2008).

89. Lord, S. J., Velle, K. B., Mullins, R. D. & Fritz-Laylin, L. K. SuperPlots: Communicating reproducibility and variability in cell biology. J. Cell Biol. 219, e202001064 (2020).

90. Neumann, M. et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. (Berl.) 117, 137–149 (2009).

91. Hallegger, M. et al. TDP-43 condensation properties specify its RNA-binding and regulatory repertoire. Cell 184, 4680-4696.e22 (2021).

92. Hasan, R. et al. Transcriptomic analysis of frontotemporal lobar degeneration with TDP-43 pathology reveals cellular alterations across multiple brain regions. Acta Neuropathol. (Berl.) 143, 383–401 (2022).

93. JP Ling, O. P., JC Troncoso, PC Wong. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349, 650–655 (2015).

94. Arnold, E. S. et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl. Acad. Sci. U. S. A. 110, E736–E745 (2013).

95. Prudencio, M. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest 130, 6080–6092 (2020).

96. Humphrey, J., Emmett, W., Fratta, P., Isaacs, A. M. & Plagnol, V. Quantitative analysis of cryptic splicing associated with TDP-43 depletion. BMC Med. Genomics 10, 1–17 (2017).

97. Polymenidou, M. et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 2011 144 14, 459–468 (2011).

98. Trabzuni, D. et al. MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum. Mol. Genet. 21, 4094–4103 (2012).

99. Park, S. A., Ahn, S. I. & Gallo, J. M. Tau mis-splicing in the pathogenesis of neurodegenerative disorders. BMB Rep. 49, 405 (2016).

100. Giesert, F. et al. Expression Analysis of Lrrk1, Lrrk2 and Lrrk2 Splice Variants in Mice. PLOS ONE 8, e63778 (2013).

101. La Cognata, V., D’Agata, V., Cavalcanti, F. & Cavallaro, S. Splicing: is there an alternative contribution to Parkinson’s disease? neurogenetics 16, 245–263 (2015).

102. Rosas, I. et al. Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer’s disease. Neurobiol. Aging 87, 139.e1-139.e7 (2020).

103. Manek, R., Nelson, T., Tseng, E. & Rodriguez-Lebron, E. 5′UTR-mediated regulation of Ataxin-1 expression. Neurobiol. Dis. 134, 104564 (2020).

104. Banfi, S. et al. Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat. Genet. 7, 513–520 (1994).

105. Carlo, A.-S., Nykjaer, A. & Willnow, T. E. Sorting receptor sortilin—a culprit in cardiovascular and neurological diseases. J. Mol. Med. 92, 905–911 (2014).

106. Hu, F. et al. Sortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin. Neuron 68, 654–667 (2010).

107. Xu, S.-Y. et al. Regional and Cellular Mapping of Sortilin Immunoreactivity in Adult Human Brain. Front. Neuroanat. 13, (2019).

108. Pallesen, L. T. & Vaegter, C. B. Sortilin and SorLA Regulate Neuronal Sorting of Trophic and Dementia-Linked Proteins. Mol. Neurobiol. 45, 379–387 (2012).

109. Mohagheghi, F. et al. TDP-43 functions within a network of hnRNP proteins to inhibit the production of a truncated human SORT1 receptor. Hum. Mol. Genet. 25, 534–545 (2016).

110. Ebert, T., Tran, N., Schurgers, L., Stenvinkel, P. & Shiels, P. G. Ageing – Oxidative stress, PTMs and disease. Mol. Aspects Med. 86, 101099 (2022).

111. Chiang, C.-H. et al. Structural analysis of disease-related TDP-43 D169G mutation: linking enhanced stability and caspase cleavage efficiency to protein accumulation. Sci. Rep. 6, 21581 (2016).

112. Mann, J. R. et al. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. Neuron 102, 321-338.e8 (2019).

113. Grese, Z. R. et al. Specific RNA interactions promote TDP-43 multivalent phase separation and maintain liquid properties. EMBO Rep. 22, e53632 (2021).

114. Keating, S. S., Bademosi, A. T., San Gil, R. & Walker, A. K. Aggregation-prone TDP-43 sequesters and drives pathological transitions of free nuclear TDP-43. Cell. Mol. Life Sci. 80, 95 (2023).

115. Maharana, S. et al. RNA buffers the phase separation behavior of prion-like RNA binding proteins. Science 360, 918–921 (2018).

116. Arnold, W. D. et al. Electrophysiological motor unit number estimation (MUNE) measuring compound muscle action potential (CMAP) in mouse hindlimb muscles. J. Vis. Exp. 2015, (2015).

117. Shefner, J. M. Motor unit number estimation in human neurological diseases and animal models. Clin. Neurophysiol. 112, 955–964 (2001).

118. Gruijs da Silva, L. A. et al. Disease-linked TDP-43 hyperphosphorylation suppresses TDP-43 condensation and aggregation. EMBO J. 41, e108443 (2022).

119. Li, H.-Y., Yeh, P.-A., Chiu, H.-C., Tang, C.-Y. & Tu, B. P. Hyperphosphorylation as a Defense Mechanism to Reduce TDP-43 Aggregation. PLOS ONE 6, e23075 (2011).

120. Wu, L. S. et al. Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons. Acta Neuropathol. Commun. 7, 50 (2019).

121. LaClair, K. D. et al. Depletion of TDP-43 decreases fibril and plaque β-amyloid and exacerbates neurodegeneration in an Alzheimer’s mouse model. Acta Neuropathol. (Berl.) 132, 859–873 (2016).

122. Ni, J. et al. Loss of TDP-43 function underlies hippocampal and cortical synaptic deficits in TDP-43 proteinopathies. Mol. Psychiatry (2021) doi:10.1038/s41380-021-01346-0.

123. Halliday, G. et al. Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathol. (Berl.) 124, 373–382 (2012).

124. Gerrits, E. et al. Neurovascular dysfunction in GRN-associated frontotemporal dementia identified by single-nucleus RNA sequencing of human cerebral cortex. Nat. Neurosci. 25, 1034–1048 (2022).

125. Baker, M. et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916–919 (2006).

126. Sieben, A. et al. The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol. (Berl.) 124, 353–372 (2012).

127. Greaves, C. V. & Rohrer, J. D. An update on genetic frontotemporal dementia. J. Neurol. 266, 2075–2086 (2019).

128. Sheen, V. L. et al. Mutations in ARFGEF2 implicate vesicle trafficking in neural progenitor proliferation and migration in the human cerebral cortex. Nat. Genet. 36, 69–76 (2004).

129. Sekiguchi, M. et al. ARHGAP10, which encodes Rho GTPase-activating protein 10, is a novel gene for schizophrenia risk. Transl. Psychiatry 10, 1–15 (2020).

130. Cuttler, K., Hassan, M., Carr, J., Cloete, R. & Bardien, S. Emerging evidence implicating a role for neurexins in neurodegenerative and neuropsychiatric disorders. Open Biol. 11, 210091.

131. Duan, Y. et al. Semaphorin 5A inhibits synaptogenesis in early postnatal- and adult-born hippocampal dentate granule cells. eLife 3, e04390 (2014).

132. Jung, J. S. et al. Semaphorin-5B Controls Spiral Ganglion Neuron Branch Refinement during Development. J. Neurosci. 39, 6425–6438 (2019).

133. O’Connor, T. P. et al. Semaphorin 5B mediates synapse elimination in hippocampal neurons. Neural Develop. 4, 18 (2009).

134. Kantor, D. B. et al. Semaphorin 5A Is a Bifunctional Axon Guidance Cue Regulated by Heparan and Chondroitin Sulfate Proteoglycans. Neuron 44, 961–975 (2004).

135. Telese, F. et al. LRP8-Reelin-Regulated Neuronal Enhancer Signature Underlying Learning and Memory Formation. Neuron 86, 696–710 (2015).

136. Beffert, U. et al. Modulation of Synaptic Plasticity and Memory by Reelin Involves Differential Splicing of the Lipoprotein Receptor Apoer2. Neuron 47, 567–579 (2005).

137. Reddy, S. S., Connor, T. E., Weeber, E. J. & Rebeck, W. Similarities and differences in structure, expression, and functions of VLDLR and ApoER2. Mol. Neurodegener. 6, 30 (2011).

138. Hinrich, A. J. et al. Therapeutic correction of ApoER2 splicing in Alzheimer’s disease mice using antisense oligonucleotides. EMBO Mol. Med. 8, 328–345 (2016).

139. Hardingham, N., Dachtler, J. & Fox, K. The role of nitric oxide in pre-synaptic plasticity and homeostasis. Front. Cell. Neurosci. 7, (2013).

140. Calabrese, V. et al. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 8, 766–775 (2007).

141. Sun, L. et al. Attenuation of epigenetic regulator SMARCA4 and ERK‐ETS signaling suppresses aging‐related dopaminergic degeneration. Aging Cell 19, e13210 (2020).

142. Zhu, X. et al. Activation of MKK6, an upstream activator of p38, in Alzheimer’s disease. J. Neurochem. 79, 311–318 (2001).

143. Alam, J. & Scheper, W. Targeting neuronal MAPK14/p38α activity to modulate autophagy in the Alzheimer disease brain. Autophagy 12, 2516–2520 (2016).

144. Waragai, M. et al. Importance of adiponectin activity in the pathogenesis of Alzheimer’s disease. Ann. Clin. Transl. Neurol. 4, 591–600 (2017).

145. Shi, F. et al. Comparative Analysis of Multiple Neurodegenerative Diseases Based on Advanced Epigenetic Aging Brain. Front. Genet. 12, (2021).

146. Guix, F. X., Uribesalgo, I., Coma, M. & Muñoz, F. J. The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol. 76, 126–152 (2005).

147. Chong, C.-M. et al. Roles of Nitric Oxide Synthase Isoforms in Neurogenesis. Mol. Neurobiol. 55, 2645–2652 (2018).

148. Seto, M. et al. Exploring common genetic contributors to neuroprotection from amyloid pathology. Brain Commun. 4, fcac066 (2022).

149. Berning, B. A. & Walker, A. K. The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD. Front. Neurosci. 13, (2019).

150. Lou, E. et al. Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma. PloS One 7, e33093 (2012).

151. Beltran, A. A. et al. Generation of an induced pluripotent stem cell line (UNCCi002-A) from a healthy donor using a non-integration system to study Cerebral Cavernous Malformation (CCM). Stem Cell Res. 54, 102421 (2021).

152. Battaglia, R. A. et al. Site-specific phosphorylation and caspase cleavage of GFAP are new markers of Alexander disease severity. eLife 8, e47789 (2019).

153. C, B. et al. Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 144, (2011).

154. Chambers, S. M. et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27, 275–280 (2009).

155. Shi, Y., Kirwan, P. & Livesey, F. J. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat. Protoc. 7, 1836–1846 (2012).

156. Carpenter, A. E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006).

157. Stirling, D. R. et al. CellProfiler 4: improvements in speed, utility and usability. BMC Bioinformatics 22, 433 (2021).

158. Anderson, K. R. et al. CRISPR off-target analysis in genetically engineered rats and mice. Nat. Methods 15, 512–514 (2018).

159. Concordet, J.-P. & Haeussler, M. CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Res. 46, W242–W245 (2018).

160. Haeussler, M. et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 17, 148 (2016).

161. Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184–191 (2016).

162. Truett, G. E. et al. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). BioTechniques 29, 52, 54 (2000).

163. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 10–12 (2011).

164. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).

165. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417–419 (2017).

166. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

167. R Core Team. R: A Language and Environment for Statistical Computing. (2022).

168. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).

169. Kassambara, A. ggpubr: ‘ggplot2’ Based Publication Ready Plots. (2020).

170. Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer-Verlag New York, 2016).

171. Conway, J. R., Lex, A. & Gehlenborg, N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics 33, 2938–2940 (2017).

172. Krassowski, M., Arts, M. & Lagger, C. krassowski/complex-upset: v1.3.3. (2021) doi:10.5281/zenodo.5762625.

173. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinforma. Oxf. Engl. 32, 2847–2849 (2016).

174. Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47, W191–W198 (2019).

175. Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J. & Peterson, H. gprofiler2 -- an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. Preprint at https://doi.org/10.12688/f1000research.24956.2 (2020).

176. Gu, Z. & Hübschmann, D. Simplify enrichment: A bioconductor package for clustering and visualizing functional enrichment results. Genomics Proteomics Bioinformatics (2022) doi:10.1016/j.gpb.2022.04.008.

177. Li, Y. I. et al. Annotation-free quantification of RNA splicing using LeafCutter. Nat. Genet. 2017 501 50, 151–158 (2017).

178. Knowles, D. A. et al. leafviz: A standalone version of the Leafcutter Shiny App. (2022).

179. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res. 29, e45 (2001).

180. Wang, X., Spandidos, A., Wang, H. & Seed, B. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res. 40, D1144–D1149 (2012).

181. Stringer, C. & Pachitariu, M. Cellpose 2.0: how to train your own model. 2022.04.01.486764 Preprint at https://doi.org/10.1101/2022.04.01.486764 (2022).

182. Stringer, C., Wang, T., Michaelos, M. & Pachitariu, M. Cellpose: a generalist algorithm for cellular segmentation. Nat. Methods 18, 100–106 (2021).

183. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).

184. Motulsky, H. J. & Brown, R. E. Detecting outliers when fitting data with nonlinear regression – a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics 7, 123 (2006).

There is NO Competing Interest.

Fig2SuppFig1.png
Figure 2 - Figure supplement 1: Generation, characterization, and genotyping of TDP-43^K145Q knock-in mice A A schematic of the TDP-43 protein and its functional domains highlights the location of lysine 145 (K145) in the TDP-43 RNA-binding domain (RRM1). B Schematic of mouse Tardbp gene targeted with a validated guide RNA, g79T above, along with donor nucleotides to insert the K145Q mutation. Two silent mutations were included to create a Hinf1 enzyme digestion site to facilitate genotyping. C Chromatograph following Sanger sequencing confirms the inserted K145Q mutation in founder animals and subsequently propagated generations. D Gel electrophoresis of DNA fragments produced following PCR amplification of the modified Tardbp region and subsequent incubation of the PCR product with Hinf1 enzyme, which yielded a 550bp band in TDP-43^wt animals (wt/wt), both 378 bp and 172 bp bands in TDP-43^KQ/KQ (KQ/KQ) animals, and all three bands in heterozygous animals (wt/KQ).
Fig3SuppFig2.png
Figure 3 – Figure supplement 2: Human iPSC-derived cortical neuron differentiation A Schematic representation of the timeline of neuronal differentiation detailing culture conditions and identity markers at each cell stage. B Brightfield images illustrating cell morphology during the differentiation process on day 2 (Top), day 12 (middle) and day 45 (bottom). Scale bars = 650 μm (top and middle) and 125 μm (bottom). C Immunofluorescence staining of SOX1 (green) and PAX6 (green) in NPCs at day 12, as well as MAP2 (red), SATB2 (cyan), GABA (green) and B-III tubulin (red) in mature cortical neurons at day 46. DAPI (blue) is used to label the nucleus. Scale bars = 125 μm
Fig4SuppFig1.png
Figure 4 – Figure supplement 1: Heterozygous TDP-43^wt/KQ animals exhibit mild cognitive and behavioral deficits at levels intermediate to TDP-43^wt and TDP-43^KQ/KQ mice A Body weight of TDP-43^wt_,TDP-43^wt/KQ, and TDP-43^KQ/KQ mice in males [left panel; F(2,59)=7.794, p=0.001] and females [right panel; F(2,59)=8.744, p=0.0006] at different ages. B Quantification of time in the center region of an open field in mice at 12 months [left panel; F(2,28)=2.54, p=0.0964] and 18 months [right panel; F(2,32)=3.79, p=0.0329]. C Quantification of time spent frozen (immobile) following context-dependent conditioned fear testing at 12-months old [left panel; F(2,28)=1.43, p=0.255] and 18-months-old [right panel; F(2,33)=9.13, p=0.0007]. D Quantification of time spent frozen following cue-dependent conditioned fear testing at 12-months-old [left panel; F(2,28)=3.624, p=0.0398] and 18-months-old. Filled bars represent presence of auditory cue (tone) and period of statistical analysis. E-F Morris Water Maze (MWM) analysis displaying time to find a hidden platform (escape latency), quantified as daily trial means per animal (E) or average across all days (F). G-H Quantification of escape latencies during MWM reversal learning trials in daily trials (G) [F(2,32)=2.788, p=0.0765] and comparing averages per mouse across all days (H).
Bar and scatter plots shown as mean ± SD. Box and whiskers show line at median, ‘+’ at mean, and whiskers run min to max. A Two-way ANOVA followed by Tukey’s multiple comparisons tests. B-D,E,G Two-way repeated measures ANOVA followed by Tukey's multiple comparisons tests. F, H One-way ANOVA followed by Tukey’s multiple comparisons testing. F statistics and p-values in legend represent main effect of genotype. Sample sizes as follows unless otherwise indicated: 12-month TDP-43^wt n=15; 12-month TDP-43^wt/KQ n=9; 12-month TDP-43^KQ/KQ n=7; 18-month TDP-43^wt n=10; 18-month TDP-43^wt/KQ n=17; 18-month TDP-43^KQ/KQ n=9; one 18-month TDP-43^KQ/KQ extreme outlier removed for MWM analysis (E,F). Statistical significance is represented by asterisks *p<0.05, **p<0.01, ***p<0.001; ns=not significant.
Fig4SuppFig3.png
Figure 4 – Figure supplement 3: Lack of overt motor deficits in TDP-43^KQ/KQmice up to 18 months of age A Quantification of distance travelled by TDP-43^wtand TDP-43^KQ/KQ mice during open field assays at 12 and 18 months of age. B Quantification of swim velocity during Morris Water Maze testing in mice at 18 months old. C-D Assessment of latency to fall off an accelerating rotarod in TDP-43^wtcompared to TDP-43^KQ/KQ mice at 18-months-old quantifying five individual trials (C) and the average latency to fall over all five trials at 6-, 9-, or 18-months old (D). E Grip strength in forepaws and all paws measured by digital force meters shows no genotype differences in grip strength at 18 months old. Scatter plots shown as mean ± SD. Box and whiskers show line at median, ‘+’ at mean, and whiskers run min to max. A,C Two-way repeated measures ANOVA followed by Holm-Šídák's multiple comparisons tests; B,D,E Two-way ANOVA followed by Holm-Šídák's multiple comparisons tests. Sample sizes as follows: 6- and 9-month TDP-43^wt n=10; 6 and 9-month TDP-43^KQ/KQ n=8; 12-month TDP-43^wt n=15; 12-month TDP-43^KQ/KQ n=7; 18-month TDP-43^wt n=10; 18-month TDP-43^KQ/KQ n=9; one extreme outlier from 18-month TDP-43^KQ/KQgroup removed for Open Field analysis (A).
Fig5SuppFig1.png
Figure 5 – Figure supplement 1: No evidence of astrogliosis or microgliosis in the hippocampus or neocortex of 18-month-old TDP-43^KQ/KQ mice A-B Representative widefield microscopy images of immunofluorescent labelling of microglia (Iba1+ cells, top panel), astrocytes (GFAP+ cells, middle panel) and a DAPI counterstain (merged image, bottom panel) of 18-month TDP-43^wtor TDP-43^KQ/KQ mouse hippocampus (A) and neocortex (B). C-F Quantification of Iba1 protein expression as measured by the integrated intensity of Iba1 fluorescence relative to DAPI fluorescence in the hippocampus (C) and neocortex (E), and by the percent of the brain region occupied by Iba1 fluorescence in the hippocampus (D) and neocortex (F). G-J Quantification of GFAP protein expression as measured by the integrated intensity of GFAP fluorescence relative to DAPI fluorescence in the hippocampus (C) and neocortex (E), and by the percent of the brain region occupied by GFAP fluorescence in the hippocampus (D) and neocortex (F). SuperPlots⁸⁹ show average value per animal in a solid color bordered symbol (as mean ± SEM) over top of semi-transparent individual values from each animal. One color represents one animal. Individual datapoints in C,D,G,H represent one image of bilateral hippocampi from a coronal brain section (two sections per animal). Individual datapoints in E,F,I,J represent one image of a unilateral segment of neocortex from a coronal brain section (6 sections per animal, total of 12 cortical regions imaged). For statistical analyses in C-J, average values from n=4 TDP-43^wt and n=3 TDP-43^KQ/KQ 18-month mice were compared using unpaired student’s t-tests.
Fig6SuppFig2.png
Figure 6 – Figure supplement 2: Intermediate levels of TDP-43 hyperphosphorylation and mislocalization in the neocortex of aged heterozygous TDP-43^wt/KQ compared to TDP-43^wt and homozygous TDP-43^KQ/KQ mice A Western blot images comparing soluble and insoluble protein fractions in the neocortex from TDP-43^wt, TDP-43^wt/KQ, and TDP-43^KQ/KQ mice at 12- and 18-months of age. B Quantification of soluble TDP-43 protein levels in hippocampus tissue relative to total transferred protein (TTP) [F (2, 17) = 3.110, p=0.0706]. C Quantification of insoluble phosphorylated p(409/410)-TDP-43 levels in neocortex [F (2, 18) = 49.76, p<0.0001]. D Western blot images following isolation of soluble nuclear and cytoplasmic protein fractions from the neocortex of TDP-43^wt, TDP-43^wt/KQ, and TDP-43^KQ/KQ mice at 12-months of age. E-F Quantification of cytoplasmic TDP-43 measured as (E) a percent of total TDP-43 [F (2, 9) = 7.617, p=0.0116] and (F) relative cytoplasmic mislocalization of TDP-43 after normalizing to cytoplasmic/nuclear ratio of the nuclear Sp1 protein [F (2, 9) = 12.91, p=0.0023]. G Western blot images following isolation of soluble nuclear and cytoplasmic protein fractions from the neocortex of TDP-43^wt, TDP-43^wt/KQ, and TDP-43^KQ/KQ mice at 18-months of age. H-I Quantification of cytoplasmic TDP-43 measured as (H) a percent of total TDP-43 [F (2, 9) = 37.88, p<0.0001] and (I) relative cytoplasmic mislocalization of TDP-43 after normalizing to cytoplasmic/nuclear ratio of the nuclear Sp1 protein [F (2, 9) = 19.09, p=0.0006]. A-I Neocortex samples from n=4 animals for each genotype and age tested. Data are presented as mean ± SD. B-C Two-way ANOVA followed by Tukey's multiple comparisons testing. E-F,G-H One-way ANOVA followed by Tukey’s multiple comparisons testing. F statistics represent the main effect of genotype unless otherwise stated. Statistical significance represented by asterisks, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Fig7SuppFig1.png
Figure 7 – Figure supplement 1: Spinal cord tissue from TDP-43^KQ/KQ mice shows evidence of altered TDP-43 autoregulation and aberrant splicing of Sort1 compared to TDP-43^wt A Tardbp expression was analyzed by qPCR in the spinal cord of TDP-43^wt and TDP-43^KQ/KQ animals at 12- and 18-months-old [F (1, 24) = 68.79, p<0.0001]. B-C qPCR analysis of WT and TDP-43^KQ/KQ spinal cord tissue samples using primers specific for Sort1 splice variants to show (B) the ratio of Sort1-ex17b:Sort1-WT mRNA levels [F (1, 25) = 92.18, p<0.0001] and (C) total Sort1 mRNA levels. Relative expression (RQ) values in each sample were determined using the Plaff method and B-actin and Pgk1 as housekeeping genes. Data are presented as mean ± SD and F-statistic represents main effect of genotype, unless otherwise stated. Two-way ANOVA followed by Šídák's multiple comparisons test. ***p<0.001, ****p<0.0001.
Fig7SuppFig2.png
Figure 7 – Figure supplement 2: Significant correlation between differentially expressed genes (DEGs) in the neocortex and hippocampus of TDP-43^KQ/KQmice Scatterplot and smoothed linear model relating the log2 fold-change of differentially expressed genes (DEGs) in the hippocampus and neocortex of TDP-43^KQ/KQ(TDP43-KQ) compared to TDP-43^wt (TDP43-WT) mice at 18-months-old. DEGs that are only significant in the hippocampus are colored in blue, DEGs that are significant only in the neocortex are colored in green, and DEGs significant in both tissues are colored in pink. Log2 fold-changes were moderately correlated (Pearson correlation coefficient R=0.61) and the relationship was statistically significant (p<0.0001).
SuppFile3KRTOligos07.19.23.xlsx
Supplementary Figure 3
SuppFile4KRTAntibodies07.19.23.xlsx
Supplementary Figure 4
SuppFile1af07.19.2023.xlsx
Supplementary Figure 1
SuppFile2a07.29.23.xlsx
Supplementary Figure 2
SUPPLEMENTARY.docx

Download PDF

Version 5

posted

You are reading this latest preprint version

RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy

Status:

Version 5

Abstract

Figures

Introduction

Results

Discussion

Methods

Declarations

References

Additional Declarations

Supplementary Files

Status:

Version 5